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In our 2002 Annual report, we show that it is difficult to
capture ‘the European drug problem’ in one statement, as
it presents a very diverse picture. Trends and levels of illicit
drug use differ between countries and regions, as well as
between its different aspects and consequences. Looking
solely at national averages may mask strongly diverging
trends at regional or local level. However, where increases
are still noted in some indicators in some countries or re-
gions, the general picture seems now more similar to a
stable ‘endemic’ situation, with constant recruitment and
exit rates. This is contrary to the situation in the 1980s and
first half of the 1990s, when many countries in the Euro-
pean Union experienced extreme and epidemic rises in
drug use and related problems.
The long-time reported increases in cannabis use show
signs of stabilisation in some countries, although at
markedly different levels, while cannabis and cocaine
problems may now be increasing. For problem drug use,
7 out of 15 countries have adjusted their estimates up-
wards, suggesting some increase although at the same
time most countries report a relative stability. Overall, HIV
prevalence seems stable; however, levels differ strongly
between countries and important increases are found in
some regions and subgroups of injectors. The number of
acute drug-related deaths seems now to have reached a
plateau, but trends are divergent between countries.
Prices of most drugs seem generally stable or decreasing.
Yet, even if ‘the drug problem’ in the European Union
seems now to have become an established phe-
nomenon, there is clearly no room for complacency.
There are an estimated two to nine problem drug users
per 1 000 of the population aged 15 to 64. In some
areas, over 25 % of injecting drug users are infected with
HIV, and HCV prevalence continues to be extremely
high (40 to 90 %). Between 7 000 and 8 000 acute drug-
related deaths occur every year, and, worryingly,
increases are seen in some countries where trends were
previously stable or decreasing. Risk of death is up to 20
times higher among opiate users than in their non-drug
using peers of the same age. The number of clients in
treatment has increased and even if treatment facilities
are also expanding, they are still clearly not sufficient,
especially in prisons. It is therefore paramount that the
political effort put into tackling the drug problem is con-
tinued and even stepped up.
We do note more consensus about the measures to
address some of the principal problems, and evidence
Preface
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on their effectiveness is increasing. For example, the
value of low-threshold services and the importance of
access to sterile injecting equipment to reduce blood-
borne infections are widely acknowledged. The protec-
tive effect of methadone maintenance on mortality and
morbidity, the additional value of voluntary drug-free
treatment and the role of medically-assisted treatment in
reducing illegal drug consumption, risky behaviour and
crime are now broadly recognised.
The widespread recognition of the value of these mea-
sures is a contributing factor, perhaps, to the relative
convergence of public policy in the areas of prevention
and treatment in the European Union. We must bear in
mind that this convergence, taking place especially in
the social and health areas, is occurring in a non-
uniform way across countries — for example, the distri-
bution of syringes is much more developed in some
countries than in others. The approach is also not neces-
sarily consistent within a country — substitution treat-
ment may be widely available in treatment centres, for
example, but much less so in prisons.
Nevertheless, national political and legislative ap-
proaches are increasingly promoting similar social and
public health measures. In many countries, prominent de-
velopments in the legislative area include moves to target
substances regardless of their legal status, to widen the dis-
tinction between drug users and drug-law offenders, to re-
duce or remove penalties for personal use or possession of
cannabis and to strengthen the legal framework for substi-
tution treatment. Focus in the prevention area has turned
to assuring the quality of interventions through introdu-
cing national standards and accreditation procedures.
The growing consensus in the European Union clearly
points towards greater efficiency and effectiveness in
continuing the fight against drug problems, by reducing
morbidity, mortality, stigma and social exclusion among
problem users, while giving truthful information about
potential risks to non-problematic users. It also repre-
sents a stronger and united response to the great priority
European citizens have given to addressing the drug
problem. I trust that this 2002 Annual report will make
an important contribution towards establishing an evi-
dence base for sound policy-making and strategic plan-
ning, both at national and local as at the European level.
Georges Estievenart
Executive Director

Overview
Drug situation
Drug use in the general population
• Use of illegal substances is concentrated among
young adults and particularly males in urban areas,
although some spreading to smaller towns and rural
areas may be taking place.
• Recent cannabis use (last 12 months) was reported by
5 to 15 % of young adults in most countries. Recent
amphetamine use was reported by 0.5 to 6 %,
cocaine use by 0.5 to 3.5 %, and ecstasy use by
0.5 to 5 %.
• Lifetime experience of cannabis is reported by 10 to
30 % of European adults, while amphetamines, co-
caine and ecstasy have been tried by about 1 to 5 %.
• Cannabis use increased markedly during the 1990s in
most EU countries, particularly among young people,
although in recent years its use may be levelling off
in some countries. Cocaine use may have increased
in recent years in some countries, although this trend
is less clear.
Problem drug use
• In general, levels of problem drug use seem stable,
although some countries do report changes in esti-
mates which taken together suggest increases of
problem drug use since 1996.
• Possible increases at national level are reported from
Belgium and Norway (data available only for injec-
tors), Germany, Italy, Luxembourg, Sweden and the
United Kingdom.
• Estimates of problem drug use are all between two
and nine cases per 1 000 population aged 15 to 64.
• Estimates of injecting drug use are in general between
two and five cases per 1 000 population aged 15 to 64.
Treatment demand
• Countries report an increase in the number of clients
in treatment.
• Opiates remain the main substance for clients seek-
ing treatment, followed by cannabis, cocaine and
amphetamines. Many differences are found among
countries.
• Trends per drug among new clients entering treat-
ment show that the number of heroin users remains
stable or decreasing, and cannabis users are increas-
ing in some countries (Germany, Denmark). The
number of cocaine clients — rising in number until
last year — now seems stable.
• The main routes of administration among new clients
are injecting for heroin (45.9 %), sniffing for cocaine
(47.1 %), eating/drinking for stimulants (56.4 %).
• The social conditions for drug users are worse than 
in the general population of the same age, namely
higher unemployment rates and lower levels of 
education.
Drug-related infectious diseases
• Levels of HIV infection roughly vary from 1 % in the
United Kingdom to 34 % in Spain but in general they
are stable.
• HIV prevalence was over 25 % among injecting drug
users (IDUs) routinely tested in drug treatment in the
Italian regions of Emilia-Romagna, Lombardy and
Sardinia, in France, in Lisbon and Porto in Portugal,
and in Spain.
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• Increases in HIV transmission (in subgroups of IDUs)
may have occurred in regions or cities in Ireland,
Italy, the Netherlands, Portugal and Finland.
• HCV prevalence is extremely high in all countries
and settings, with infection rates of between 40 and
90 % among different subgroups of IDUs.
Drug-related deaths
• In all, 7 000 to 8 000 acute drug-related deaths are
reported each year in the EU, and the real number of
cases is probably higher. Opiates are present in most
overdose deaths, although presence of additional
substances is frequent.
• There is a relatively stable trend at EU level, although
with divergent national trends. However, it is worry-
ing that some EU countries report recent new
increases after a period of stabilisation or decrease.
• Mortality of opiate users, in particular injectors, is up
to 20 times higher than the general population of the
same age, due to overdoses, infectious diseases, acci-
dents, suicides, etc. 
Drug-related crime
• In all countries — except Norway, the Netherlands,
Italy and Spain — drug law offences reported by the po-
lice continue to concern mainly drug use/possession.
• According to prisons and countries, between 29 and
86 % (over 50 % in most studies) of prisoners report
having ever used an illicit drug.
• Though most drug users tend to stop or reduce their
drug use after imprisonment due to the low availabil-
ity of illicit drugs, some continue to use drugs, and
others commence once incarcerated.
Drug markets and availability
• Cannabis is the most seized drug in all countries
except Portugal (heroin). In 2000, quantities seized
went down in most of the Member States.
• At EU level, the number of seizures of cannabis and
ecstasy continued to increase in 2000, while they
decreased for heroin, cocaine and amphetamines.
• In 2000, a marked decrease in the quantities of
cocaine seized was reported — mainly due to high
decreases in countries seizing most of the cocaine in
the EU (Spain, France, the Netherlands).
• The price of all illicit drugs is generally stable or
decreasing in the EU, although some increases were
reported regarding brown heroin.
Responses to drug use
National strategies
• The recent tendency to produce strategic responses to
the drugs situation continues. Objectives and targets
are better identified than in the past. Implementation
and evaluation are now the main challenges for
national drug strategies.
• Increased attention is given to prevention and treat-
ment activities regarding alcohol and tobacco. Strate-
gies tend to target the substances causing addiction
regardless of their legal status.
National legislation
• There is a trend to widen the distinction between
drug users and other drug law offenders, either
through legal or policy distinctions, or by establishing
a more specialised court system, or both.
• At the same time, a number of countries have chosen
to reduce or remove penalties for personal use or pos-
session of cannabis, distinct from other substances.
• New legislation on drugs in road traffic specifies indi-
viduals and methods for testing, and may improve
statistical collection to serve as a scientific base for
future legislation on the topic.
• National legal frameworks for substitution treatment
are being established or strengthened.
Demand reduction
• All national drug strategies include priorities in the
field of responses. School prevention is seen as a prior-
ity in ten Member States, prevention and early inter-
vention for young people at risk in nine, and responses
in the criminal-justice system in seven. Eight countries
see a need to strengthen treatment structures.
• The quality of demand-reduction responses is assured
with the introduction in some countries of national
standards, accreditation procedures or guidelines.
Prevention in schools, 
local settings and the community
• All Member States stress the high priority of preven-
tion and report numerous preventive activities in dif-
ferent settings, at schools most notably. However,
there is a substantial gap between policy aims and
the reality and quality of prevention.
• Objectives for school prevention range from all-
inclusive health promotion principles, the develop-
2002 Annual report on the state of the drugs problem in the European Union and Norway
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ment of social/personal skills to the promotion of
identity/personality. Awareness and information are
often prominent, although such approaches alone
have proven ineffective.
• Wide disparities exist between Member States con-
cerning the role of mass media in prevention strate-
gies — from none at all to very prominent.
Prevention in recreational settings
• Prevention in recreational settings is based on three
intervention strategies: the production of information
material on drugs; personalised interventions in dis-
cotheques or raves; and structural measures such as
safe-clubbing guidelines.
• The value of on-site pill testing interventions for
intense interactive preventive counselling has been
overshadowed by discussions focusing on questions
of its pharmacological accuracy and its legal implica-
tions.
Prevention of infectious diseases
• Evidence-based responses to prevent infectious dis-
eases among drug users are hepatitis immunisation,
drug treatment — in particular the prescription of
substitution drugs — community-based outreach,
access to sterile injection equipment and safer use
information and training.
• Access to sterile injecting equipment is of major im-
portance for minimising the rate of HIV and other
blood-borne viral infections. Even though syringe ex-
change programmes have become more widely avail-
able, the coverage of the target population shows large
differences between and within countries.
• Hepatitis immunisation rates among drug users are
very low. Systematic efforts are underway in some
countries to make the vaccination more accessible.
Prevention of drug-related deaths
• A significant proportion of overdoses could be avoided.
• Methadone maintenance has a substantial protective
effect on mortality from opioid overdose.
• Innovative approaches to preventing and managing
overdoses are reported from some countries — such as
the training of drug users to protect themselves and to
better manage overdoses they witness, naloxone ad-
ministration training as well as basic resuscitation tech-
niques, or the development of specific prevention infor-
mation materials.
Availability of treatment facilities
• The past five years have seen a considerable increase
in the availability of treatment facilities in the EU and
Norway. Medically-assisted treatment appears to
have grown more rapidly than drug-free treatment.
• Evaluations of drug-free treatment interventions have
shown that it is effective. Evaluation results fluctuate,
but generally 30 to 50 % of clients entering drug-free
treatment complete it successfully.
• Medically-assisted treatment with methadone or
buprenorphine has proved effective in reducing the
consumption of illegal drugs, risk behaviour and
crime. Sufficient dosages have shown to be impera-
tive to ensuring positive outcomes. Accompanying
psycho-social interventions contribute to success, but
are still underdeveloped.
Criminal-justice responses
• Judicial authorities in EU countries dispose of a range
of measures at different stages of the criminal-justice
system to divert into treatment drug users who have
committed a criminal offence. 
• Most EU countries have abstinence-oriented treat-
ment programmes and/or drug-free units inside pris-
ons. However, the number of places is, compared to
the estimated number of prisoners with drug prob-
lems, low.
• Substitution treatment is now available in prisons in al-
most all EU countries and in Norway. However, even
in countries where a large percentage of problem drug
users in the community are in substitution treatment,
prisons often follow a detoxification policy.
• There is evidence for the need for ‘stepped care’
arrangements/continuous treatment to reduce recidi-
vism among drug using offenders.
• There is an increasing effort to document and evalu-
ate other criminal-justice system responses, but there
is not much scientific evidence (yet).
Supply reduction
• Combating organised drug trafficking is a priority for
Member States through the improvement of
database systems and crime analysis techniques, to-
gether with increased development of international
cooperation.
• Fighting against the diversion of chemical products
and precursors under control is an important part of
Overview
9
the increased international cooperation. Additional
resources to guarantee an adequate level of surveil-
lance are required.
• International customs cooperation and the activities of
the OECD Financial Action Task Force (FATF) play a very
important role in measures against money laundering.
2002 Annual report on the state of the drugs problem in the European Union and Norway
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C h a p t e r
Drug 
situation
Drug use 
in the general population (1)
Population surveys provide estimates of the proportion of
the population who have used different drugs during cer-
tain periods of time, in addition to providing information
on the behaviour and characteristics of respondents. For
illegal drugs, the more usual measures are:
• any use during the person’s life (lifetime prevalence),
often called ‘lifetime experience’ with drugs;
• any use during the previous year (last-12-months
prevalence), often called ‘recent use’ of drugs; and
• any use during the previous month (last-30-days
prevalence), often called ‘current use’ of drugs.
‘Lifetime experience’ always produces higher figures,
and is widely used in reports and assessments of a coun-
try’s drug situation. However, lifetime experience alone
does not capture well the current situation as it also
includes all those who have ever tried drugs, whether
once or a few times many years ago.
‘Recent use’ produces lower figures, but reflects better
the current situation. The combination of lifetime experi-
ence and recent use can give basic information on drug
use patterns (e.g. continuation rates). ‘Current use’ may
give some indication of regular use, but figures are gen-
erally quite low when the whole population is consid-
ered.
Many surveys investigate the age of the onset of drug use
and the frequency of use, which allow estimations of
incidence and patterns of use. Other individual variables
(sociodemographic variables, opinions and risk percep-
tions, lifestyles, health problems, etc.) can help to estab-
lish correlations between use and other individual fac-
tors.
Age ranges used to report results may have an important
influence in prevalence estimates. Comparisons should
be based on the same age groups. The EMCDDA recom-
mends the age range of 15–64 years for the whole adult
population and 15–34 years for young adults but there
are still small national differences in the data reported.
Patterns of drug use
Basic common and divergent patterns of drug use can be
identified across EU Member States, despite the methodo-
logical limitations.
Cannabis continues to be the illegal substance most
commonly used in all EU countries. Lifetime experience
is much more common than recent or current use, indi-
cating that use tends to be occasional or to be discontin-
ued after some time. There is a small proportion of users
that consume the substance daily, and particular atten-
tion should be paid to this group.
Substances other than cannabis are used by much smaller
proportions of the population, although there are consid-
erable differences between countries. In this case, too,
lifetime experience is clearly higher than recent use (2)(3).
1
(1) The methods used to estimate drug use in the general population are explained online (http://annualreport.emcdda.eu.int).
(2) Figure 1 OL: Patterns of drug use among the general population (online version). Cannabis use as example: lifetime experience
versus current use (last 30 days) in Dutch national survey 1997.
(3) Figure 2 OL: Continuation rates for some substances in recent European population surveys, among the whole adult population
(online version).
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This chapter provides an overview of the situation of drug use and supply
in the EU and Norway and highlights recent developments and emerging trends.
NB: Data are from the most recent national surveys available in each country.
For young adults, the EMCDDA uses the range 15–34 years (Denmark
and the United Kingdom from 16, Germany and Ireland from 18). Varia-
tions in age ranges may slightly influence some national differences. In
some countries, the figures were recalculated at national level to adapt
as far as possible to the standard EMCDDA age group.
Sources: Reitox national reports 2001, taken from scientific surveys, reports or arti-
cles. See also the standard epidemiological table ‘Last-12-months preva-
lence of drug use in recent nationwide surveys among the the general
population in some EU countries’ (http://annualreport.emcdda.eu.int).
Use of illegal substances is concentrated among young
adults, who have prevalence rates roughly double that of
all adults. Males outnumber women among people who
have tried drugs in all countries and all age groups,
although these differences tend to decrease in younger
groups (4). Drug use is more prevalent in urban areas,
although some spread to smaller towns and rural areas
may be taking place.
Lifetime experience of cannabis is reported to range from
10 % (Finland) to 25 to 30 % (Denmark and the United
Kingdom) of the whole adult population, with a substan-
tial number of countries reporting figures of around 20 %
(Belgium, Germany, Spain, France, Ireland and the
Netherlands). Amphetamines have been tried by 1 to
6 % of the population (11 % in the United Kingdom),
cocaine and ecstasy have been tried each by about 0.5
to 4.5 % of the population. Heroin has been tried gener-
ally by less than 1 % of the population, although by up
to 2 to 3 % of young males of some countries. As a ref-
erence outside Europe, in the 2000 US household sur-
vey, 34 % of adults (12 years and older) reported lifetime
experience of cannabis and 11 % of cocaine (5).
Recent use of cannabis is reported from 1 to 10 % of all
adults, although most countries that have information
report levels of between 5 and 10 %. Recent use of
amphetamines, cocaine or ecstasy was reported in gen-
eral by less than 1 % of adults, although Ireland and the
United Kingdom have somewhat higher figures for the
three substances, together with Denmark and Norway
for amphetamines and Spain for cocaine. In the 2000 US
household survey, 8.3 % of adults (12 years and older)
reported recent use (past year) of cannabis and 1.5 % of
cocaine.
Young adults report clearly higher rates of recent drug
use. In most countries, recent cannabis use was reported
by 5 to 18 % of young adults (Sweden 1 to 2 %). Recent
amphetamine use was reported by 0.5 to 6 %, cocaine
use by 0.5 to 3.5 % and ecstasy use by 0.5 to 5 % (6).
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(4) Figure 3 OL: Gender differences in drug use (recent use, last
12 months), reported in general population surveys of Euro-
pean countries (online version).
(5) Source: SAMHSA, Office of Applied Studies, National
household survey on drug abuse, 1999 and 2000
(http://www.samhsa.gov/oas/oas.html). Note that the age
range (12 years and over) is wider than the age range
reported by the EMCDDA for EU surveys (15–64 years).
(6) Figure 4 OL: Recent use (last 12 months) of amphetamines,
ecstasy and cocaine among young adults in European coun-
tries, measured by national population surveys (online 
version).
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Recent use (last 12 months) of cocaine among young adults, measured 
by national population surveys
Figure 1
NB: Data are from the most recent national surveys available in each country.
For young adults, the EMCDDA uses the range 15–34 years (Denmark
and the United Kingdom from 16, Germany and Ireland from 18). Varia-
tions in age ranges may slightly influence some national differences. In
some countries, the figures were recalculated at national level to adapt
as far as possible to the standard EMCDDA age group.
Sources: Reitox national reports 2001, taken from scientific surveys, reports or
articles. See also the standard epidemiological table ‘Last-12-months
prevalence of drug use in recent nationwide surveys among the general
population in some EU countries’ (http://annualreport.emcdda.eu.int).
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Figure 2
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In addition to real differences in drug use, several factors
can contribute to differences in national figures. Overall
national figures can be explained in part by generational
factors, including the convergence between the lifestyles
of males and females. Shares of urban population in each
country may explain in part some overall national figures.
Comparative analysis and policy formulation and evalua-
tion should take into consideration precise age groups,
gender and urbanisation, among other criteria (7)(8).
Trends in drug use among 
the general population
It is difficult to define clear-cut trends that apply to the EU
as a whole, due to the limitations of information sources
(few consistent series) and the differences in national so-
cial/cultural context and development. Lifetime experi-
ence should be used with caution when analysing trends,
since it is an accumulative measure that will not decrease
for a long time, even if current drug use decreases.
National and local population surveys, as well as con-
script and school surveys, show that cannabis use
increased markedly during the 1990s in almost all EU
countries, particularly among young people. At the same
time, some convergence in cannabis use can be suggest-
ed across countries, with a significant number of coun-
tries reporting around 20 to 25 % of lifetime experience
and 5 to 10 % of recent use.
In more recent years, cannabis use seems to be levelling
off or even decreasing in some countries (Ireland, the
Netherlands, Finland and Norway) among young people,
conscripts or school students. However, increases con-
tinue in other countries.
European trends in other substances (e.g. cocaine, ecsta-
sy and amphetamines) are more difficult to track, which
underlines the need to maintain consistent series of sur-
veys with appropriate sample sizes.
There has been growing concern about possible increases
in cocaine use in the EU, due to increases of cocaine prob-
lems reported in some countries. Increase of recent co-
caine use seems consistent among young people in the
United Kingdom and, possibly to a lesser extent, in Den-
mark, Germany and Greece. In Spain, France and Finland,
no increase is apparent among young adults, although in
Spain figures are comparatively high and a consistent in-
crease among students has been observed (Figure 3).
Drug situation
(7) Figure 5 OL: How to look at different figures on drug use between countries — An example using Denmark and France (online
version).
(8) Figure 6 OL: Recent cannabis use (last 12 months) by age group in European countries, measured by population surveys —
Recent cocaine use (last 12 months) by age group in European countries, measured by population surveys (online version).
NB: Data taken from national surveys, available in each country. For young adults, the
EMCDDA uses the range 15–34 years (Denmark and UK from 16, Germany and Ireland
from 18, France (1992: 25–34 and 1995: 18–39)). 
(1) Although not presented in the graphic, information from Denmark and Greece sug-
gests some increases.
Sources: Reitox national reports 2001, taken from scientific surveys, reports or articles. See
also the standard epidemiological table ‘Last-12-months prevalence of drug use in
recent nationwide surveys among the general population in some EU countries’
(http://annualreport.emcdda.eu.int).
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Figure 3C
See http://annualreport.emcdda.eu.int for statistical
tables related to this section:
• Lifetime prevalence (LTP) of drug use in recent nationwide
surveys among the general population in some EU countries
• Last-12-months prevalence (LYP) of drug use in recent nation-
wide surveys among the general population in some EU
countries
• School surveys: lifetime prevalence among students, 15–16
years of age
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Only five Member States made data available from
school surveys during 2000 concerning school students
aged 15–16 years. Sweden showed an increase in
cannabis use and Italy showed an increase in cannabis,
ecstasy and cocaine. The other three Member States
showed either stable or declining prevalence of drug use
in this age group. 
A number of Member States conduct surveys of young
people above the 15–16 age range and outside of the
school environment. School surveys across age ranges
show that lifetime drug prevalence increases consider-
ably with age, although the level of increase varies
between countries. Compared with general population
surveys, young people in nightlife and club settings also
show much higher average prevalence for recreational
drug use; ecstasy in particular. (See Figure 4, which
should be interpreted with caution as the targeted sur-
veys are not strictly comparable.)
Drug use among young people
NB: In targeted survey n = range 100–986.
Sources: Athens: Calafat, A., Bohrn, K., Juan, M., Kokkevi, A., Maalsté, N., Mendes, F.,
Palmer, A., Sherlock, K., Simon, J., Stocco, P., Sureda, M. P., Tossmann, P., van de
Wijngaart, G. and Zavatti, P. (1999): Night life in Europe and recreative drug use,
Irefrea and European Commission, Valencia.
Amsterdam: Korf, D. J., Nabben, T., Lettink, D. and Bouma, H. (1999): Antenne 1998.
Trends in alcohol, tabak, drugs en gokken bij jonge Amsterdammers, Jellinek, Amster-
dam.
France: Médecins du Monde (1999): Techno rave parties.
London: Release (1997): Release drugs and dance survey: an insight into the culture,
Release, London.
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Problem drug use
Problem drug use is defined as ‘injecting drug use or
long-duration/regular use of opiates, cocaine and/or
amphetamines’ (9).
See http://annualreport.emcdda.eu.int for statistical
tables related to this section:
• Estimated number of problem drug users in EU Member
States, 1995–2000
• Estimated rate of problem drug users in EU Member States,
1995–2000 (rate per 1 000 aged 15–64)
In general, levels of problem drug use seem stable,
although, with the current estimation methods, data
quality and data availability, it is still not possible to reli-
ably calculate trends in the prevalence of problem drug
use in most countries.
However, some countries do report changes in estimates
and/or other indicator data, which taken together suggest
increases in problem use since 1996. Possible increases
at national level are reported from Belgium and Norway
(data available only for injectors), Germany, Italy, Lux-
embourg, Sweden and the United Kingdom, while
increases at local or regional level are reported from
some other countries (10).
Estimates of problem drug use are all between two and
nine cases per 1 000 of the population aged 15–64 (this
is using the midpoints of the estimates). The highest esti-
mates are reported for Italy, Luxembourg, Portugal and
the United Kingdom, with between six and nine problem
drug users per 1 000 inhabitants aged 15–64. Estimates
are lowest in Austria, Germany and the Netherlands,
with about three problem drug users per 1 000 inhabi-
tants aged 15–64. Data are not available from Belgium,
Greece and Norway (see Figure 5).
In Finland and Sweden, the majority of problem drug
users are primary amphetamine users (an estimated 70 to
80 % in Finland in 1997). This is contrary to other coun-
tries where problem drug users are mostly primary opiate
users (and at the same time polydrug users).
This year, separate estimates are given for injecting drug
use, a subcategory of all problem drug use. The increased
quality of the estimates based on mortality data and HIV
data enables them to be presented separately from prob-
lem drug use. Estimates of injecting drug use are in gen-
eral between two and five cases per 1 000 of the popula-
tion aged 15–64, but data are not available for six Mem-
ber States. The estimate for Luxembourg is higher, at al-
most seven per 1 000. Estimates of injecting drug use in-
dicate the population at risk for serious health conse-
quences or drug-related death (see Figure 6).
(9) More details on the definitions and methods used to estimate problem drug use are given online (http://annualreport.emcdda.eu.int).
(10) Trends and patterns per country are presented online (http://annualreport.emcdda.eu.int).
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NB: The dot shows the central estimate, while the line represents the uncertainty range or 95 % confidence interval. The longer this line, the less certain the prevalence estimate is (not available for
Spain). The Swedish estimate includes problem cannabis users (estimated to be about 8 % of the total sample).
Sources: National focal points through EMCDDA project: ’State of the art regarding national prevalence estimates of problem drug use in the EU Member States’, CT.00.RTX.23, Lisbon, EMCDDA, 2002.
Coordinated by the Institut für Therapieforschung, Munich.
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NB: The dot shows the central estimate, while the line represents the uncertainty range or 95 % confidence interval. The longer this line, the less certain the prevalence estimate is (not available for
France and the United Kingdom).
Sources: National focal points through EMCDDA project: ‘State of the art regarding national prevalence estimates of problem drug use in the EU Member States’, CT.00.RTX.23, Lisbon, EMCDDA, 2002.
Coordinated by the Institut für Therapieforschung, Munich.
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Demand for treatment
Characteristics of clients entering treatment (such as so-
cial characteristics) and consumption behaviours (such
as the proportion of injectors or opiate users) are poten-
tial indicators of wider trends in problem drug use. They
also offer a view of the organisation of treatment centres
in Europe. Biases may, however, arise owing to different
methods of information collection and the varying level
of the offer of treatment services between countries.
Substances
Despite differences in treatment policies and recording
practices, it is possible to identify both common and
divergent trends across Europe.
In 2000, countries report an increase in the overall num-
ber of people treated for drug problems. According to
the reports, this seems to be attributed to two main fac-
tors — improved methods of data collection (an
increased number of persons treated are reported) and
expansion of treatment facilities, especially those pro-
viding substitution treatment. The creation of new spe-
cialised services for specific target groups (e.g. minors)
could also have influenced this increase.
Opiates (especially heroin) remain the main substance
for clients seeking treatment in most countries. This
could be partly due to the fact that many services are
organised around the needs of opiate users. Overall,
between 50 and 70 % of clients requesting treatment are
heroin users but this varies largely between countries —
from 89.6 % in Greece to 19 % in Sweden.
The number of clients seeking treatment for cannabis as
their main illegal drug varies from 2.5 % in Portugal to
24 % in Germany. Often use of cannabis is combined with
other substances (see selected issue on polydrug use in
Chapter 3).
Spain (18 %) and the Netherlands (29 %) remain the coun-
tries with the highest percentages of clients seeking treat-
ment for cocaine as their main drug. Rates in other coun-
tries are lower — from 6 % in Germany to 0.8 % in Greece.
The widest disparity between countries is evident with am-
phetamines, with 33 % of clients in Finland and 29 % in
Sweden seeking treatment. The rate in Germany, the United
Kingdom, Denmark and the Netherlands ranges from 7 to
2 % and is around 0 % in other countries (see Figure 7).
Polydrug use is increasingly apparent in treatment data.
Trends
New clients demanding treatment for heroin appear to
be stable or decreasing. Possible reasons for this include:
the proportional increase of consumers of other drugs;
the end of the heroin epidemic evident in the late 1980s
and early 1990s (the clients commencing during this
period have already requested treatment, usually five
years after starting use); a parallel trend in prevalence
data; and the creation of new services targeted at other
consumer profiles.
The number of clients requesting treatment for cannabis
is increasing in some countries. Germany reports the
highest increase in cannabis clients requesting treatment
for the first time — from 16.7 % in 1996 to 42.6 % in
2000 (although it is important to note that these data
only refer to outpatient units). Denmark follows with an
increase from 25 % in 1996 to 30 % in 2000. Similar
trends are apparent in other countries, although not to
the same extent (Figure 8).
This increase in cannabis users is confirmed in data on
all clients admitted to treatment over the years and it is
relatively consistent among countries. Furthermore, an
increase in the use of cannabis as a secondary drug
together with another main substance is especially 
visible in clients using opiates as a main substance. This
increase does not have a clear and unique explanation
and reasons could include, among others, an increase in
the prevalence of cannabis use, an increase in the num-
ber of cases reported by the criminal-justice system and
an increase in the number of adolescents with social or
psychological problems.
2002 Annual report on the state of the drugs problem in the European Union and Norway
16
NB: * = 1999 data.
Sources: Reitox national reports 2001. See also the statistical table ‘Some characteristics of persons treated for drug problems in the EU’ (http://annualreport.emcdda.eu.int).
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This year, and for the first time, 12 of the 15 EU Member
States have provided the EMCDDA with data on clients
demanding treatment for drugs in line with the TDI 
protocol. The TDI protocol (1) is a joint EMCDDA–
Pompidou Group initiative adopted by the 15 Member
States. The information collected covers among others:
types of treatment offered; substances used; and clients’
socio-demographic details.
The data-collection exercise, covering the year 2000,
involved a total of 1 702 treatment units across Europe.
Using the same standards, the units together provided
information on 170 444 patients.
(1) A full report on the Treatment Demand Indicator is available
online (http://www.emcdda.eu.int/multimedia/project_reports/
situation/treatment_indicator_report.pdf).
Protocol on the Treatment Demand Indicator (TDI)
The increase in cocaine treatments shown in 1999 seems
to have stabilised in 2000, especially in the countries
where the increase was highest last year (the Netherlands
and Spain) but this apparent trend should be monitored in
the coming years. Cocaine consumption is reported to be
an increasing problem in European countries over recent
years and cocaine seems to play an important role as a
secondary drug combined with heroin and alcohol. How-
ever, most countries remark that persons asking for treat-
ment represent only a small percentage of cocaine users.
Routes of administration
The three routes of administration of the primary drugs
most frequently reported are: injection for heroin
(45.9 % among first treatments), sniffing for cocaine
(47.1 %) and eating/drinking for stimulants (56.4 %)
(Figure 9).
The proportion of heroin injectors varies markedly
between countries — from 13 % in the Netherlands to
73.8 % in Greece. Although a general decrease in inject-
ing heroin is quite common, an opposite trend was vi-
sible in some countries (e.g. in Finland an increase from
61.1 to 68.7 %). The rapid decrease of the injecting pat-
tern in Spain from 1991 to 2000 should be noted in par-
ticular (Figure 10). At market level, three main factors
could influence the route of administration: the relative
availability of smokeable heroin (base form) or injecting
(hydrochloride) heroin; heroin price (a higher price leads
to more injecting); and heroin purity (lower purity is
related to a higher level of injecting use).
Social characteristics
Clients entering treatment tend to be males in their 20s or
30s. The mean age is 29 years and 27 for clients entering
treatment for the first time. Ireland and Finland have the
youngest treated population, whilst Greece and the
Netherlands have the oldest clients seeking treatment (11).
The age distribution among the general population is dif-
ferent from the age distribution among clients, that is to
say that the countries with the oldest (or youngest) popu-
lation do not have the oldest (or youngest) clients in treat-
ment. Ireland and Greece are the exceptions, where the
young and the old age of clients in treatment reflects that
of their general population (12). The age distribution of
clients seeking treatment seems indeed to be related to the
type of substances consumed — in general, cannabis con-
sumers are younger, whilst heroin and cocaine users are
older. For example, the youngest clients are found in Bel-
gium, where there is the highest percentage of cannabis
consumption, whilst the oldest are found in Greece and
the Netherlands, where there is a high percentage of
heroin and cocaine consumption.
Drug situation
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Sources: Reitox national reports 2001.
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(11) Figure 7 OL: Mean age of clients in treatment (online version).
(12) Data from Eurostat (1999) have been used as a reference point for the analysis.
The gender distribution varies from a male:female ratio of
2:1 to 6:1. There is a similarity among southern countries
with a higher percentage of men and among northern
countries with a lower percentage of men. Reasons for this
distribution seem to be due to the different drug con-
sumption patterns among women and men, but could also
be due to a different approach to services among the gen-
ders. Women generally ask for services less than men,
although some studies based on comparison between
gender distribution in prevalence data and in treatment
data show that a higher percentage of women using drugs
ask for treatment.
In general, the social conditions of clients demanding
treatment are worsening compared to the general popu-
lation. There are, for example, rates of unemployment of
up to 50 to 55 %, even in countries where the unem-
ployment rate among the general population in the same
age group is less than 5 % — such as Denmark (13). Low
levels of education are also apparent. Up to 13.2 % have
not completed primary school and up to 65.8 % have
attended primary school only (14).
With regard to nationality, characteristics resemble the
general population structure: clients are mainly nationals
of the country where they request treatment and the rate
of people coming from other countries (European or
non-European) is consistent with the proportion of for-
eigners in the general population (15).
Drug-related infectious
diseases (16)
Prevalence and trends in HIV and AIDS
Infectious diseases related to injecting drug users (IDUs)
cause the largest health care costs of all types of illegal
drug use. They can be prevented by providing informa-
tion and clean injecting material to IDUs, and by vacci-
nation for the hepatitis B virus. This, and the often very
high prevalence of infections among IDUs, makes poli-
cies aimed at prevention of infections in IDUs among the
most cost-effective in the field of drugs.
The EMCDDA has only recently started to systematically
collect data on HIV and hepatitis B and C among IDUs.
Aggregated prevalence (overall and by subgroups) is col-
lected from different routine settings (drug treatment,
needle exchange, prisons, etc.) as well as from special
studies (17). Although the data obtained to present are
still difficult to compare, they provide a global sense of
differences by country or region and by setting, among
others. The longer-term aim is to improve data quality
and comparability from existing routine sources and to
set up truly comparable local European sero-prevalence
studies among injecting drug users.
As far as data are available, they suggest that large dif-
ferences exist in HIV prevalence among IDUs, between,
as well as within, countries. Levels of infection in the dif-
ferent sources roughly vary from about 1 % in the UK
(surveys and unlinked anonymous screening) to 34 % in
Spain (routine diagnostic tests in drug treatment), but
they are in general stable (18). This overall picture has
not changed in recent years (Figure 11).
In some regions, extremely high HIV prevalence has still
been found between 1996 and 2001. Although in most
cases this reflects old epidemics, special prevention
efforts are very important (e.g. efforts to prevent trans-
mission to new IDUs, to sexual partners of IDUs and
from mother to child). Prevalence was over 25 % among
IDUs routinely tested in drug treatment in the Italian
regions of Emilia-Romagna, Lombardy and Sardinia; in
France (IDUs aged over 34); in Lisbon and Porto (Portu-
2002 Annual report on the state of the drugs problem in the European Union and Norway
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(13) Figure 8 OL: Labour status in some countries (online version). 
(14) Figure 9 OL: Level of education in some countries (online version).
(15) Figure 10 OL: Percentage of non-nationals among clients in first treatment in some countries (online version). 
(16) A more detailed insight into this issue is provided in the 2001 annual report, Chapter 3, Selected issues — Drug-related infec-
tious diseases available online (http://ar2001.emcdda.eu.int). 
(17) See http://www.emcdda.eu.int/situation/themes/infectious_diseases.shtml for more detail on methods and guidelines of data col-
lection.
(18) For more detail on these data and for original sources see the complementary statistical tables online 
(http://annualreport.emcdda.eu.int).
See http://annualreport.emcdda.eu.int for statistical
tables related to this section:
• Some characteristics of persons treated for drug problems in
the EU
• Some characteristics of persons in the EU treated for drug
problems for the first time
• Some characteristics of women treated for drug problems in
the EU
• Some characteristics of men treated for drug problems in 
the EU
gal); and in Spain. Studies that included IDUs both
recruited in treatment and in out-of-treatment settings
(the latter being more representative) have also found
prevalence over 25 %, in Lisbon (Portugal), Barcelona,
Madrid, Seville (Spain, 1995), Amsterdam (the Nether-
lands) and Dundee (Scotland, 1995).
Trends over time in HIV prevalence are important for
policy and evaluation purposes. More action is needed
where trends are increasing and may be sufficient where
they are decreasing. However, in areas with decreasing
prevalence new infections may still occur. In recent
years, increases in HIV transmission in (subgroups of)
IDUs have occurred in regions or cities in Ireland, Italy,
the Netherlands, Portugal and Finland (19). The Italian
data shows that a national average is of very limited
value for policy purposes and breakdowns by smaller
regions or cities are extremely important to evaluate the
success of prevention (see Figure 12). However, very few
countries can yet provide national data broken down by
region. Decreases in HIV prevalence were found in IDUs
in treatment in the Italian regions of Lazio, Marche and
Umbria and in needle exchange attendees in Helsinki,
Finland, in 2000 (following the earlier strong increase in
1998/99). For following trends over time, the prevalence
data are complemented by notifications of newly diag-
nosed cases. Although not yet available for the most
affected countries, and still much depending on testing
patterns, notification data have helped identify the new
increases in transmission in Finland (Figure 13).
Prevalence in young IDUs may provide further feedback
on the effectiveness of prevention, as they will on aver-
age have been infected more recently than the total
group. Prevalence in IDUs aged less than 25, for those
countries where a breakdown by age was available, was
highest in Spain (drug treatment, declining from 20 % in
1996 to 13 % in 2000), France (declining from 6 % in
1997 to 3 % in 1999 in drug treatment, but 8 % in 1998
in needle exchange attendees), Italy (drug treatment, 8 %
Drug situation
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(19) See Box OL:  Increases in HIV transmission among IDUs in some EU countries (online version) for details. 
NB: Data in brackets are local. Differences between countries have to be
interpreted with caution due to different source types and in some cases
local data. Colour for a country indicates the midpoint of the range in
prevalence from the different data sources. Data for Spain, Italy and Ger-
many are limited to HIV prevalence among IDUs in treatment and may
not be representative of HIV prevalence among IDUs who are not in
treatment. The high figure for Portugal refers to a study in a very prob-
lematic area in Lisbon. 
Sources: Reitox national focal points. For primary sources see the summary and
full tables ‘Prevalence of HIV infection among injecting drug users in the
EU, 1996–2001’ (http://annualreport.emcdda.eu.int).
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NB: Regions with stable or low trends have been omitted. Total sample size is 70 000 per
year. All trends significant (p < .01) except fot Basilicata, Molise and Trentino. For
more detail see the table ‘Prevalence of HIV infection (% infected) among injecting
drug users in the EU, 1996–2001’ (http://annualreport.emcdda.eu.int).
Source: Rivelazione attività nel settore tossicodipendenze — Anno 2000, ministero della
Salute, sistema informativo sanitario, Direzione generale della prevenzione, Ufficio
Dipendenze da farmaci e sostanze d’abuso e AIDS.
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in 1998) and among IDUs in drug treatment in Portugal:
Coimbra (7 % in 1999/2000), Lisbon (6 to 11 % in
1998–2000), Porto (57 % in 1997).
For some countries, information is available on HIV
prevalence in new injectors. This is an even better indi-
cator for recent HIV infections (HIV incidence) and thus
stronger evidence for the effectiveness of prevention
measures. In new injectors, incidence per 100 person-
years of exposure may vary from 0 in England and Wales
(prevalence 0/122, 1998), 3.9 in the Belgian Flemish
Community (3/77, 1998/99), 9.4 in Coimbra, Portugal
(12/127, 1999–2000) to 10 in France (11/111, self-report-
ed serostatus in needle exchange attendees, 1998) 
(Figure 13).
AIDS data can no longer be used to follow trends in HIV
infection, due to improved HIV treatments that delay the
onset of AIDS. AIDS incidence, however, still shows the
burden of newly occurring HIV disease in the different
countries. AIDS incidence has dropped in most countries
since about 1996, due to the improved treatments and
possibly lower infection rates in the 1990s. In Portugal,
IDU-related AIDS continued increasing in the late
1990s, indicating a lack of HIV treatment uptake and/or
increased HIV transmission among IDUs. The increase in
Portugal has stabilised since 1997, leaving the country
with the highest yearly incidence of AIDS among IDUs
in the EU (20).
Prevalence and trends in infection 
with the hepatitis C virus
Data on prevalence of infection with the hepatitis C virus
(HCV) are less available and, where available, are sub-
ject to the same limitations as the HIV data. However,
the overall picture is also clear — HCV prevalence is
extremely high in all countries and settings, with infec-
tion rates of between 40 and 90 % among different sub-
groups of IDUs (Figure 14).
Although all prevalence figures show very high levels of
infection, the range in prevalence is still large. As for
HIV, this may partly reflect different selection mecha-
nisms in the different data sources, and comparisons
should be made with caution. Several countries have not
reported updated figures. In 2000 and 2001, levels over
75 % were reported for Antwerp, Belgium (80 % in drug
treatment and low threshold services 2001), northern
Greece (83 % in methadone treatment), the Italian
regions of Piedmont, Trentino, Friuli-Venezia Giulia, Lig-
uria, Emilia-Romagna, Basilicata and Sardinia (drug
treatment), and some smaller cities in Portugal, outside
Lisbon (drug treatment) (21).
For injecting risk behaviour and for measuring the effec-
tiveness of prevention, trends in HCV prevalence can be a
much more sensitive indicator than trends in HIV. HCV is
more infective than HIV and can be transmitted more eas-
ily through injecting materials other than syringes, such as
cotton, spoons, water (but very much less easily sexually).
Increasing trends in HCV prevalence are reported from
Frankfurt (drugs emergency service), northern Greece
(methadone treatment) and some regions in Italy (drug
treatment: Piedmont, Trentino, Emilia-Romagna, Marche,
Basilicata and Sardinia, consistent with increases in HIV in
some of those regions). Decreases are reported from Aus-
tria (drug treatment and low threshold services), Lisbon,
Portugal (drug treatment), Helsinki, Finland (needle ex-
changes), London, UK (drug treatment), and other Italian
regions (Veneto, Tuscany, Umbria and Abruzzi), once
more demonstrating the policy relevance of monitoring
2002 Annual report on the state of the drugs problem in the European Union and Norway
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NB: Data in brackets are local. Differences between countries have to be
interpreted with caution due to different types of sources and/or local
data. Colour for a country indicates the midpoint of the range in preva-
lence from the different data sources. Data for Spain, Italy and Portugal
are limited to HCV prevalence among IDUs in treatment and may not be
representative of HCV prevalence among IDUs who are not in treatment.
Data from the UK, Luxembourg and Finland are based on saliva tests.
The data for France are based on self-reported test results, which may
be unreliable. The Swedish data are for 1994. 
Sources: National focal points. For primary sources see the statistical table
‘Prevalence of HCV infection among injecting drug users in the EU,
1996–2001’ (http://annualreport.emcdda.eu.int).
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(20) Figure 11 OL: Incidence of AIDS related to IDU in EU Member States (online version).
(21) Further country and regional details can be found online (http://annualreport.emcdda.eu.int) (online version).
prevalence not only nationally, but also by region, city or
other small area.
As far as they are available, data on prevalence in IDUs
aged under 25 indicate levels of HCV infection of from
about 20 % (Flemish Community, Belgium, treatment,
1997/98) to over 74 % (Coimbra, Portugal, treatment,
2000). Prevalence in young IDUs seems to be decreas-
ing in France (43 % 1997 to 37 % in 1999), but data
are based on self-reported test results and may be un-
reliable.
Prevalence data of HCV in new injectors (injecting less
than two years) are still not available from most sources.
Where data are available, in general they indicate
prevalence of 40 % or higher. This suggests that new
injectors are infected at very high rates. However, it
cannot be excluded that acute infections are over-repre-
sented, and thus prevalence overestimated in sources
reporting prevalence among routine diagnostic testing
(Coimbra, Portugal) or based on self-reported test results
(France). In community-wide surveys in England and
Wales, rates in new injectors as low as 2 % are report-
ed from outside London. This suggests that incidence of
new infections is very low and possibly that HCV pre-
vention efforts in England and Wales are relatively effec-
tive (see Figure 15).
Prevalence and trends 
in the hepatitis B virus
Antibodies for the hepatitis B virus (HBV) indicate
whether somebody has ever been infected or vacci-
nated. Thus, the proportion with no antibodies, i.e. the
potential for vaccination among IDUs, is important to
know for vaccination policy. Antibody prevalence for
HBV seems less similar across the EU than prevalence
of HCV. In the EU, roughly between 20 and 60 % of
IDUs have antibodies against hepatitis B, suggesting a
large potential for vaccination programmes (40 to
80 %).
Current hepatitis B infection can be either a recent or
chronic infection, and is indicated in the blood by a
serological marker named HbsAg. Levels of current
infection indicate the potential for severe long-term
complications and for spread to others through inject-
ing risk behaviour or sexual transmission. Prevalence
of current HBV infection is only available from a lim-
ited number of countries, but appears to differ much
and is in some cases high. In northern Greece, IDUs in
methadone programmes may have experienced an
important outbreak of hepatitis B infection prior to
1998, as levels were extremely high in 1998 but
declined strongly between 1998 and 1999. In Belgium,
data from IDUs in treatment indicate a steady increase
in current HBV infection between 1997 and 1999. In
Portugal, recent drug treatment data indicate a decline
in current HBV infection. In Norway, notification data
indicate a strong increase in current HBV (and HAV)
infections among IDUs.
Drug situation
21
Sources: National focal points. For primary sources see the table ‘Prevalence of HCV infection
among new injecting drug users, 1996–2000’ (http://annualreport.emcdda.eu.int). The
95% confidence interval is indicated. 
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See http://annualreport.emcdda.eu.int for the detailed
statistical tables related to this section:
• Summary table of ‘Prevalence of HIV infection among inject-
ing drug users in the EU, 1996–2001’
• Summary table of ‘Prevalence of HCV infection among
injecting drug users in the EU, 1996–2001’
• Prevalence of HIV infection among injecting drug users in
the EU, 1996–2001
• Prevalence of HIV infection among injecting drug users
under age 25, EU, 1996–2000
• Prevalence of HIV infection among new injecting drug users
in the EU, 1996–2000
• Notified cases of HIV among injecting drug users in the EU,
1991–2001
• Prevalence of HCV infection among injecting drug users in
the EU, 1996–2001
• Prevalence of HCV infection among injecting drug users
under age 25, EU, 1997–2000
• Prevalence of HCV infection among new injecting drug users
in the EU, 1996–2000
• Prevalence of current hepatitis B infection (HbsAg) among
injecting drug users in the EU, 1996–2001
• Prevalence of HBV antibodies among injecting drug users in
the EU, 1996–2001
Drug-related deaths 
and mortality among drug users
The number of ‘drug deaths’ is often used in public
debates and the media, and in discussions about illegal
drug problems. These deaths create serious social con-
cern and can influence the formulation and evaluation of
drug policies.
National statistics on ‘drug deaths’ usually refer to acute
deaths directly related to drug consumption or ‘over-
doses’ (22). The definition used in the EMCDDA key indi-
cator also refers to these deaths (23). In addition, problem
drug users — in particular opiate users — suffer a high
overall mortality rate mainly due to overdoses, but also
due to AIDS, accidents, violence, etc.
Impact and characteristics 
of acute drug-related deaths
The impact of acute drug-related deaths becomes evi-
dent when it is considered that each year between 7 000
and 8 000 deaths are reported by EU countries. Most
countries consider that there is some level of under-
notification, in some cases significant under-notification.
Opiates are present in most cases of overdose deaths,
although concentrations found in toxicology vary widely,
with very frequent presence of other substances, which
in some cases may play a contributory role to the fatal
outcome.
Most victims of overdoses are young males, in their 20s
or 30s, who have been using opiates for several years.
Injection represents a major risk factor, whereas non-
injectors have a lower risk of overdose. Similarly to
clients entering treatment, a clear ageing trend among
victims is observed in most countries. Finland, and to a
lesser extent, the United Kingdom are exceptions to this
ageing trend (24)(25).
There is enough information to conclude that a signifi-
cant proportion of overdoses (fatal and non-fatal) could
be avoided. Firstly, some risk factors for opiate overdoses
are known: injection in comparison to other routes;
combined use with other depressants; use after a period
of abstinence (e.g. after prison or treatment release);
injecting alone; and probably unexpected changes in
purity. In addition, most overdoses happen in the pres-
ence of other users, and usually death is not immediate,
allowing time for intervention. However, reactions of
witnesses are often inappropriate or delayed, due to lack
of knowledge or fear of police intervention.
For the time being, deaths due to intoxication by cocaine,
amphetamine or ecstasy without the presence of opiates are
infrequent in Europe. However, several countries (Spain,
France, Italy, the Netherlands and the United Kingdom)
have reported national or local increases of cases where co-
caine is found (generally in addition to other substances). In
addition, some deaths related to cocaine may take the form
of cardiovascular problems and pass unnoticed.
Deaths directly caused by ecstasy are unusual, but they
raise serious concern because they happen unexpected-
ly among very young people, and because some could
be prevented through simple measures, such as proper
ventilation and the availability of water in dance places,
in addition to health education.
Methadone has been detected in a certain number of
deaths, although several sources (e.g. from the United
Kingdom or Germany) indicate that deaths involving
methadone were more likely to be the result of illicit
rather than prescribed use. It should be underlined that
research shows that substitution programmes reduce the
risk of mortality among programme participants.
Trends in acute drug-related deaths
In a long-term perspective of trends in EU countries
(15–20 years), a marked increase of drug-related deaths
was observed during the 1980s and early 1990s. During
recent years, the number of acute deaths has stabilised at
this higher level of between 7 000 and 8 000 per year in
the EU as a whole, although with different national
trends (Figure 16).
It is worrying that some EU countries report recent increases
after a period of stabilisation or decreases. Other countries,
such as Australia and the United States, have also reported
increases of opiate-related deaths in recent years.
These overall trends may be explained by the expansion of
heroin injection in many European countries during the
1980s and early 1990s. The recent levelling off might be
2002 Annual report on the state of the drugs problem in the European Union and Norway
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(22) Box 1 OL: Definitions of ‘acute drug-related death’ in EU Member States, as used in the EMCDDA annual report and reported in
national reports (online version).
(23) Box 2 OL: Drug-related deaths — EMCDDA definition (online version).
(24) Table 1 OL: Summary of characteristics of deceased due to acute drug-related deaths in the EU (online version).
(25) Figure 12 OL: Evolution of the proportion of people over 35 years among drug-related deaths in some EU countries (online 
version).
related to the stabilisation of the prevalence of problem
drug use in some countries, the decrease in risk practices
(injection) in others and, probably, the increase of treat-
ment availability — including substitution programmes.
The fact that there are no indications of a decrease at EU
level underlines the reality that drug-related health dam-
age is far from being overcome, stresses the need to fur-
ther investigate risk factors and reinforces the need for
appropriate targeted interventions. It is important to
stress that within the overall EU trend described, differ-
ent, and sometimes divergent, national trends exist.
Several countries presented a downward trend during
the second half of the 1990s (Germany, Spain, France,
Italy, Luxembourg and Austria), possibly for the reasons
mentioned above. In some of them the decrease or 
stabilisation has continued (Spain, France and Italy).
However, it is worrying that, in others, the 
number of reported deaths has increased again in recent
years (Germany, Luxembourg and Austria) (Figure 17).
The ageing of problem drug users and the increase in
polydrug use are considered to be contributing factors.
Some countries reported substantial upward trends in the
second half of the 1990s (e.g. Greece, Ireland, Portugal and
Norway). In Ireland (1999) and Portugal, this trend has been
halted. Finland presents an increasing trend in recent years,
with an increase of the number of young people among the
deceased. These increases may be related to the later ex-
pansion of heroin use in these countries, although improved
reporting systems may have played a role in some cases.
The United Kingdom has presented a steady, although
moderate, increasing trend of drug-related deaths. Their
national definition includes medicine-related deaths, but
if heroin–morphine cases are considered independently,
a more marked upward trend is evident.
Other countries present less clearly defined trends, or
changes are more difficult to interpret, due to the switch
between ICD classifications (from 9th to 10th edition) or
changes in national definitions.
Overall mortality among problem drug users
Problem drug users account for less than 1 % of the adult
population of the EU but significant health and social
problems are concentrated within this limited group. Even
several city-based studies have shown that a significant
proportion of the mortality of young adults in the EU can
be attributed to problem drug (in particular opiate) use.
For instance, in Glasgow, a third of deaths among those
aged 15–35 years could be attributed to acute drug deaths
during the early 1990s and, in Madrid, a quarter of deaths
among males aged 15–39 years in 1990 were attributed to
overdoses or AIDS related to drug injection. Further stud-
ies are needed to monitor the impact of drug-related mor-
tality in other places and in more recent years.
Mortality cohort studies show that mortality among prob-
lem drug users is up to 20 times higher than among the
general population of the same age. This high mortality is
due mainly to overdoses, but also due to AIDS and other
infectious diseases, accidents, suicides, etc. Overdoses
and external causes account for an important part of this
mortality, in particular in countries with low HIV preva-
lence among drug users, whereas AIDS plays a significant
role in countries with high HIV prevalence. Chronic
health problems (cirrhosis following hepatitis, cancer,
etc.) may play an important role in the longer term.
Drug situation
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NB: Indexed: 1985 = 100 %. Not all countries provided data for all years, but this situation
has been controlled in the computation of the overall trend — EMCDDA project report
CT.99.RTX.04, coordinated by the Trimbos Instituut.
Sources: Reitox national reports 2001, taken from national mortality registries or special reg-
istries (forensic or police). Based on national definitions as presented in Box 1 OL:
Definitions of ‘acute drug-related death’ in EU Member States, as used in the 
EMCDDA annual report and reported in national reports.
(1) Figure 13 OL: Historical trends in acute drug-related deaths in EU countries,
1985–2000 (online version). 
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Figure 16
NB: The figures presented are for proportional variations over 1985 (or the first year with
available information). The series begins in 1986 for Luxembourg to avoid distortion of
the graphic (it would reach 2 700 in 2000).
Sources: Reitox national reports 2001, taken from national mortality registries or special reg-
istries (forensic or police). Based on national definitions as presented in Box 1 OL:
Definitions of ‘acute drug-related death’ in EU Member States, as used in the 
EMCDDA annual report and reported in national reports.
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Mortality of injectors is two to four times higher than
non-injectors and (until recently) mortality of drug users
infected by HIV was two to six times higher than non-
infected users. With recent improvements in HIV treat-
ment, this difference might be decreasing. 
Mortality of problem drug users other than opiate users
or non-injectors seems clearly lower, although new
methodological approaches may be needed to assess
mortality among these users.
Trends in mortality among problem 
drug users
The multi-site study coordinated by the EMCDDA shows
differences in overall mortality rates and distribution of
causes of death between participating sites. The study
also reveals relevant changes over time in overall and
cause-specific mortality.
Barcelona presented the highest mortality rates and Vien-
na and Dublin the lowest. In several locations, mortality
rates were higher during the early or mid-1990s and
have decreased in recent years. In Barcelona, rates were
particularly high between 1992 and 1996, but have
decreased sharply in recent years, due mainly to the
decrease in AIDS mortality. In Lisbon, mortality rates
have been increasing until recent years (Figure 19).
Direct comparisons across sites should be made with
caution, since profiles of recruitment centres are differ-
ent, although in general they would tend to represent the
common types of treatment available. With this limita-
Drug-related crime
Drug-related crime can be considered as covering criminal
offences against drug legislation, crimes committed under
the influence of illicit drugs, economically driven crimes
committed by users to support their drug habit (mainly ac-
quisitive crime and dealing) and systemic crimes commit-
ted as part of the functioning of illicit markets (fight for ter-
ritories, punishment of dealers, etc.). Except for drug law
offences, these categories do not transpose into routinely
available data and when available come from ad hoc local
studies that are difficult to extrapolate.
Arrests (26) for offences against national drug legislation
(use, possession, trafficking, etc.) reflect differences in law
as well as priorities and resources for law enforcement.
Differences in recording procedures and definitions affect
comparisons. Whenever possible, trends are compared.
2002 Annual report on the state of the drugs problem in the European Union and Norway
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NB: Direct comparability across study sites has still some limitations. There are some differences in typology of recruitment settings (treatment centres) and treatment modalities, although treatment
settings and modalities tend to represent common types of treatment available in each site. See Table 2 OL: Characteristics of cohorts enrolled. Several cohorts recruited a proportion of their cases
through inpatient drug treatment services. Clients recruited through inpatient services might not be fully comparable to other samples of treated clients.
Sources: EMCDDA projects CT.99.EP.07 and CT.00.EP.13, coordinated by the Department of Epidemiology, Rome E Health Authority.
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Figure 18
(26) The term ‘arrest’ covers different concepts, varying between countries (police reports of suspected drug law offenders, charges for
drug law offences, etc.). Please refer to the online table on ‘arrests’ for an exact definition per country.
See http://annualreport.emcdda.eu.int for tables 
related to this section:
• Number of ‘acute drug-related deaths’ recorded in EU coun-
tries (according to national definitions used to report cases to
the EMCDDA), 1985–2000
• Box 1 OL: Definitions of ‘acute drug-related death’ in EU
Member States, as used in the EMCDDA annual report, and
reported in national reports
• Box 2 OL: Drug-related deaths — EMCDDA definition
tion in mind, trends on overall and cause-specific rates
within each site can give valuable insights.
Cannabis remains in 2000 the most common drug in-
volved in ‘arrests’ — accounting for 37 % of the drug-re-
lated arrests in Sweden and up to 85 % in France. In Por-
tugal and Luxembourg, heroin is predominant while in the
Netherlands, most of the drug offences are related to ‘hard
drugs’ (drugs other than cannabis and its derivatives) (27).
The majority of reported drug offences are related to
drug use or possession for use — from 55 % in Portugal
to 90 % in Austria. In Norway, 60 % relate to drug deal-
ing and trafficking. In Italy, the Netherlands and Spain,
where drug use is not considered as a criminal offence,
all drug offences relate to dealing or trafficking. As in
previous years, Luxembourg reports the highest number
of arrests involving offences for both drug use and drug
trafficking.
Trends
In the EU as a whole, ‘arrests’ for drug law offences have
been steadily increasing since 1985. Increases by over
10-fold were reported in Greece and Portugal while in
Denmark, Luxembourg, the Netherlands and Sweden,
increases were much lower (less than twofold).
Over the last three years, the number of drug-related
‘arrests’ increased in most EU countries. The highest
increases were reported by Greece, Ireland and Norway.
In 2000, the Netherlands and the United Kingdom were
the only countries reporting a fall in the number of drug-
related ‘arrests’ (28) (Figure 20).
Drug situation
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NB: These ‘observed mortality rates’ represent the average for the whole follow-up period in each site (in brackets). In each study site there have been significant changes over time (see Figure18). If
‘observed rates’ were presented year by year these rates would change. See Table 2 OL: ‘Characteristics of cohorts enrolled’. Several cohorts recruited a proportion of their cases through inpa-
tient drug treatment services. Clients recruited through inpatient services may not be fully comparable to other samples of treated clients.
Sources: EMCDDA projects CT.99.EP.07 and CT.00.EP.13, coordinated by the Department of Epidemiology, Rome E Health Authority.
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Figure 19
(27) Figure 14 OL: Drug mostly involved in the ‘arrests’ for drug offences in EU countries (online version). 
(28) There was a fall in ‘arrests’ in Belgium too, but it is due to a change in recording procedures. 
NB: For definitions of arrests for drug offences, please refer to the statistical table Num-
ber of ‘arrests’ for drug law offences in EU countries and Norway, 1985–2000 (online
version). Real values have been input for all countries in 2000, for Finland in 1998 and
for Belgium in 1995 and 1997, since data available do not allow the calculation of
moving averages in these cases. The series is discontinued for Belgium in 1996 (data
not available).
Sources: Reitox national focal points.
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Figure 20
See http://annualreport.emcdda.eu.int for statistical
tables related to this section:
• Drug mostly involved in the ‘arrests’ for drug offences in EU
countries and Norway
• Offence type mostly involved in the ‘arrests’ for drug offences
in EU countries and Norway
• Number of ‘arrests’ for drug law offences in EU countries and
Norway, 1985–2000
• References to graph ‘Arrests for drug offences, 1991–2000.
Three-year moving averages indexed (1991 = 100)’
Drug markets and availability
Drug seizures are usually considered as indirect indicators of
supply and availability of drugs, although they reflect law en-
forcement resources, priorities and strategies, as well as vul-
nerability of traffickers to enforcement. Quantities seized may
fluctuate from one year to another due to a small number of
large seizures (29). For this reason, the numbers of seizures are
usually considered as a better indicator of trends (30). In all
countries, they include a major proportion of small seizures
from the retail level of the market. Where known, origin and
destination of drugs seized may indicate trafficking routes
and producing areas. Price and purity of drugs at retail level
are reported by most of the Member States, but data are too
scarce to allow for accurate comparisons.
Cannabis
Cannabis is the most seized drug in every Member State ex-
cept Portugal, where heroin seizures predominate. Since
1996, Spain has been seizing the largest quantities of
cannabis, more than half the total amount seized in the EU.
The United Kingdom reports a higher number of cannabis
seizures but on average they involve smaller quantities.
Cannabis resin comes mainly from Morocco via Spain and
the Netherlands. The cannabis herb originates in
Afghanistan, Pakistan and Lebanon, as well as coming
from Albania to Italy and Greece, and from Angola to Por-
tugal. Local production takes place in most Member States,
especially ‘nederwiet’ (31) production in the Netherlands.
In 2000, the retail price of cannabis was reported to vary
between EUR 1 and EUR 20 per gram of cannabis resin
and between EUR 2 and EUR 8 per gram of cannabis
leaves. The percentage of THC content in cannabis resin
ranges between 2 and 13 % on average, although sam-
ples ranging from 0 to 50 % of THC have been reported
in the EU. The THC content in cannabis leaves is gener-
ally lower, around 1 to 6 %, with the exception of Bel-
gium (17 % on average) and ‘nederwiet’ in the Nether-
lands, which rates higher (10 % on average).
Trends
The number of cannabis seizures has increased steadily
in the EU since 1985 and seems to have stabilised over
the last three years. This trend is especially due to a
decreasing number of cannabis seizures in Belgium, the
Netherlands, Portugal, Austria and the United Kingdom
in recent years. Quantities increased too, but have sta-
bilised since 1995. In 2000, quantities seized went down
in most of the Member States.
The price of cannabis is generally stable in the EU, although
increasing in Luxembourg and Portugal (resin) in 2000.
Heroin
In 2000, almost 9 tonnes of heroin were seized in the EU, of
which over a third was accountable to the United Kingdom
(Figure 21). Heroin seized in the EU comes mainly from the
Golden Crescent (south-west Asia: Afghanistan and Pak-
istan), followed by the Golden Triangle (south-east Asia:
Myanmar, Laos and Thailand), via Turkey, the Balkan route
and the Netherlands. However, increased trafficking via
eastern Europe (Russia, Estonia, Bosnia and Slovenia) and
central Asian countries from the former USSR was reported.
At street level, heroin prices varied between EUR 25 and
EUR 330 per gram in 2000 across the EU. The highest
prices are reported by Ireland, Finland and Norway.
Heroin purity ranges typically from under 20 to 45 %,
but higher average purity is reported by Belgium, Den-
mark, Spain and Norway regarding brown heroin.
Trends
At EU level, heroin seizures increased up until 1991–92 and
then stabilised. In 2000, they decreased in Ireland, Luxem-
bourg, Norway, Portugal and Spain. Compared to the situa-
tion in 1985, quantities seized at EU level have been in-
creasing. They stabilised during the period 1991–98, but
have been increasing again since then. In 2000, all coun-
tries, except Denmark, Germany, Spain, Italy and Sweden,
reported increases in the amount of heroin seized.
Heroin street prices are generally stable or decreasing,
though brown heroin was reported to increase in 2000
in Portugal, Sweden and the United Kingdom. Heroin
purity is reported to be stable or decreasing in all coun-
tries, except Denmark, Germany, Luxembourg and the
United Kingdom, where it has been recently increasing,
especially brown heroin.
Cocaine
Spain remains the country in the EU with the highest level of
cocaine seizures. The cocaine used in Europe comes from
Latin America (especially Colombia, Brazil and Venezuela)
via Central America and the Caribbean. For several countries,
Spain is the main entry point to the rest of the EU, although
cocaine is then often redistributed via the Netherlands.
2002 Annual report on the state of the drugs problem in the European Union and Norway
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(29) Figure 15 OL: Quantities of cannabis, cocaine, heroin and amphetamines seized in EU countries (1985–2000) (online version). 
(30) Caution is required when analysing trends at EU level, as series start at different years in different countries. See the statistical
tables (http://annualreport.emcdda.eu.int) for more information. 
(31) ‘Nederwiet’: Dutch cannabis leaves grown locally in the Netherlands.
The retail price of cocaine varied from EUR 45 to
EUR 170 per gram in 2000. The lowest prices are
found in Spain and the United Kingdom, and the high-
est in Finland. Cocaine purity is generally high, be-
tween 50 and 85 % in most countries, except in Den-
mark and Germany, where it was on average lower in
2000.
Trends
The total number of cocaine seizures rose steadily since the
mid-1980s in the EU and stabilised in 2000. The quantities
of cocaine seized had been fluctuating within an upward
trend but, in 2000, a marked decrease was reported —
mainly due to very large decreases in countries seizing most
of the cocaine in the EU (Spain, France and the Netherlands).
Cocaine prices are stable or decreasing in most coun-
tries, but increased in 2000 in Denmark, Portugal and
the United Kingdom. Purity remains stable or is decreas-
ing in every Member State.
Synthetic drugs: amphetamines, 
ecstasy and LSD
In Finland, Norway and Sweden, amphetamines are the
second most commonly seized drug (after cannabis). The
United Kingdom accounts for most of the amounts of
amphetamines, ecstasy and LSD seized in the EU.
The Netherlands is a major site for the production of
ecstasy, amphetamines and related drugs but evidence of
production in other Member States (Belgium and the
United Kingdom) and in east European countries (the
Czech Republic and Estonia) is also reported.
Amphetamines are reported to be sold at between EUR 5
and EUR 35 per gram on average, while ecstasy tablets
vary from EUR 5 to EUR 15 each. Data for 2000 show that
synthetic drugs are cheaper in Belgium and the United
Kingdom. Amphetamine purity is very variable, from 3 %
in Ireland to 46 % in Finland, but is typically between 10
and 15 % in the EU. In 2 % of cases in Greece to 100 % in
Finland, tablets sold as ecstasy contain ecstasy or ecstasy-
like substances (MDMA, MDEA, MDA). Amphetamines
(or metamphetamines) are found in 2 to 22 % of tablets,
but various other psychoactive substances (2-CB, 2-CT7,
4-MTA and recently PMA and PMMA) may also be found.
Trends
Amphetamine seizures — both numbers and quantities —
have been rising since 1985. The number of amphetamine
seizures went down in 1999 and 2000, especially in the
United Kingdom. After decreases in 1998 and 1999, quan-
tities rose again in 2000, particularly in Germany.
Ecstasy seizures have been increasing in most of the
EU since 1985, with marked increases in 2000.
Amounts of ecstasy seized followed the same upward
trend since 1985, and then stabilised from 1993 to
peak in 1996 and increase again since 1999. In 2000,
they rose in all countries except Denmark, Luxem-
bourg and Portugal.
LSD seizures are less common. Both numbers and quan-
tities went up until 1993, decreased from then, but rose
Drug situation
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NB: n.a. = data not available.
Sources: Reitox national focal points, 2000. See statistical tables ‘Number of
heroin seizures, 1985–2000’ and ‘Quantities of heroin seized, 1985–2000
(kg)’ (http//:annualreport.emcdda.eu.int).
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NB: Data are not available for Greece. For some other countries, data are only available
since 1988 (Denmark and Portugal), 1993–96 (Finland) and 1997 (the Netherlands).
Numbers of seizures are underestimated in 1999 and 2000, since data are missing for
Italy. Most of the ecstasy data series start in the mid-1990s (except France, Italy,
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Sources: Reitox national focal points. See the statistical tables on ‘Drug seizures in the EU
countries and Norway, 2000’ (http://annualreport.emcdda.eu.int).
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slightly in 2000. Denmark, Germany, Spain, France, Ire-
land, the Netherlands, Portugal and Finland report major
increases in quantities of LSD seized in 2000.
After significant decreases in the 1990s, amphetamine and
ecstasy prices have stabilised in the EU. However, in
2000, Ireland reported an increase in both synthetic drug
prices, while Germany reported a rise for amphetamine
only. Spain, Sweden and the United Kingdom reported
cheaper ecstasy tablets in 2000. In recent years, the pro-
portion of tablets containing ecstasy or ecstasy-like sub-
stances has increased in many countries while those con-
taining amphetamines (and metamphetamines) decreased.
Greece reported a shift from MDMA to amphetamines as
the main substance in the majority of tablets in 1999 and
2000.
2002 Annual report on the state of the drugs problem in the European Union and Norway
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See http://annualreport.emcdda.eu.int for statistical
tables related to this section:
• Drug seizures in the EU countries and Norway, 2000
• Number of amphetamine seizures, 1985–2000
• Number of cannabis seizures, 1985–2000
• Number of cocaine seizures, 1985–2000
• Number of ecstasy seizures, 1985–2000
• Number of heroin seizures, 1985–2000
• Number of LSD seizures, 1985–2000
• Quantities of amphetamine seized, 1985–2000 (kg)
• Quantities of cannabis seized, 1985–2000 (kg)
• Quantities of cocaine seized, 1985–2000 (kg)
• Quantities of ecstasy seized, 1985–2000 (tablets)
• Quantities of heroin seized, 1985–2000 (kg)
• Quantities of LSD seized, 1985–2000 (doses)
C h a p t e r
icy document has continued, although a gap between
the written strategy and its implementation still remains.
In March 2001, the Portuguese Government approved an
action plan on drugs entitled Horizonte 2004, which iden-
tifies detailed objectives, goals and specific actions to be
developed over a period of four years. One month later, the
Irish Government approved a national drugs strategy for
the period 2001–08 which elaborates specific objectives,
key performance indicators and individual actions to be
taken by each minister involved in the delivery of drugs
policy. In June, the Greek Ministerial Council adopted a
number of decisions directed towards a holistic, unified
and coordinated policy on drugs. In these decisions, the
government commits itself to introducing to parliament a
five-year national action plan with specific targets to be
met, activities to be developed and measures to be taken.
In Finland, an action plan for 2001–03 was adopted (in
February 2002) and specific drug strategies drawn up be-
tween customs and the frontier guard. In Austria, all nine
provinces now have a drugs or addiction coordinator and
seven have drugs action plans while, in Belgium, the Cel-
lule drogue santé was created in June 2001 and a coordi-
nation body is planned for the end of 2002. Italy, follow-
ing the new government approach on drugs, announced
the creation of an anti-drugs department headed by a drug
coordinator, in November 2001. In Germany, a team of
Länder coordinators has been working on improving co-
ordination for many years. In January 2002, the Swedish
Government presented its new drugs action plan for
29
Responses 
to drug use
National and European 
drug strategies
Drug policy into action plans
EU strategy
In October 2001, the Council’s Horizontal Working
Party on Drugs examined the ‘Report on the identifica-
tion of criteria for an evaluation of the European Union
strategy on drugs (2000–04)’, drawn up by the EMCDDA
and Europol. It offers an analysis of each of the six tar-
gets of the EU action plan (32) and underlines monitoring
and evaluation potentials and constraints. It also
includes a set of parameters on which to establish a situ-
ation baseline using 1999 data (33) and against which the
situation in 2004 will be measured.
National drugs strategies (34)
The EU action plan on drugs has contributed to promot-
ing awareness on the need for coordinated activities in
Member States in the field of drugs. Article 1.1.3 calls on
the Council to provide regular opportunities for those
responsible for drugs at national level to meet and
exchange information on national developments and
increase cooperation. In Sweden, one such meeting was
organised among national drug coordinators in 2001 (35).
As far as national strategies are concerned, the trend
established over the past few years to translate drug pol-
icy frameworks into an action plan, drug strategy or pol-
2
(32) Details on the EU drugs strategy and action plan can be found online (http://www.emcdda.eu.int/policy_law/eu/eu_actionplan.shtml).
(33) Available online (http://snapshot.emcdda.eu.int). 
(34) Table 3 OL: Action plans and coordinators (online version). 
(35) The EMCDDA contributed with the publication of a comparative study on drug coordination in the EU
(http://www.emcdda.eu.int/multimedia/project_reports/policy_law/drug_coordination_oct_01.pdf).
This chapter presents an overview of developments in national and EU drug policies
and strategies. Responses to the drugs problem in the fields of education, health, 
social care and criminal justice are also covered.
2002–05 before the parliament. A ‘drug commissioner’
has also been appointed to coordinate and stimulate the
actions at different levels of society.
In the United Kingdom, contrary to the general tendency,
responsibility for drugs within government was moved
from the Central Drug Coordination Unit (now dissolved)
and its ‘drug tsar’ in the Cabinet Office to the Home Office
and lies under the responsibility of the Secretary of State
for Home Affairs.
Assessment of the impact of the drug strategies
Although all Member States have now more or less
defined drug strategies, the assessment of their impact is
not yet common practice. Progress has been made in
evaluating specific programmes or activities, usually in
the demand-reduction field. However, when legal instru-
ments or national strategies are considered as a whole,
evaluation does not feature as a priority.
A few promising examples among the newly adopted
strategies can, however, be mentioned. In Ireland and
Portugal, the new national drugs plans adopted in 2001
both aim to establish evaluation mechanisms to assess
their overall results. In Finland, evaluation is part of the
new action plan for 2001–03 and it will concern the
effectiveness of the plan as a whole, including treatment
measures and actions relating to drug control.
In France, the Observatoire français des drogues et des
toxicomanies (OFDT) has received a mandate from the
mission interministérielle lutte contre la drogue et la toxi-
comanie (MILDT) to evaluate the effectiveness of the most
important aspects of the French drugs plan for 1999–2001.
Evaluation is a priority in the Netherlands, not only with
regard to demand-reduction programmes but also with re-
gard to other policy aspects (e.g. the coffee shop policy
and changes in AHOJ-G criteria). The extended monitor-
ing practices (national drug monitor) in the field of drug
use and health — and related development of activities in
law enforcement criminal justice — also contribute to the
evaluation of policies. Other national drug strategies an-
nounce evaluation as a tool for measuring individual ac-
tivities such as treatment methods or prevention tech-
niques, as for example in the new Belgian ‘political note’
where evaluation is to be applied to treatment methods,
health, care circuits and prevention techniques.
Member States look at legal and illegal substances
together
Increased attention to legal and illegal substances in
drugs national policies is visible. If France was among
the first countries to extend reflection on preventive and
rehabilitative measures in terms of addiction and not just
on substances in 1998, over the last year the Norwegian
Government further developed a comprehensive ‘sub-
stance abuse policy’ including alcohol, with regard to
prevention, care and treatment. In Germany, the new
Federal Drug Commissioner’s report in April 2001 also
highlighted its intention to extend prevention, above all,
to legal drugs, alcohol and tobacco. In Belgium, one of
the four aims of the new federal government policy is to
prevent young people from using drugs (including to-
bacco and alcohol). This trend is also apparent in the
new drug strategy in Ireland, where in 2001 formal links
at local, regional and national levels with the national
alcohol policy have been developed to ensure comple-
mentarity between the different measures being under-
taken. In the United Kingdom, in May 2001 the Northern
Ireland Executive endorsed a joint implementation
model. Through this structure, the strategies on alcohol
and illicit drugs will be taken forward together. The
Welsh drug strategy also includes legal substances.
Drug laws in the EU (36)
At European level
On 23 May 2001, the European Commission adopted
the proposal of a Council framework decision laying
down minimum provisions on the constituent elements
of criminal acts and penalties in the field of illicit drug
trafficking. This Commission initiative provides a com-
mon definition of illicit drug trafficking as well as com-
mon penalties concerning large-scale transnational traf-
ficking. The proposal is currently (March 2002) being
examined by the European Parliament and the Council
of Ministers of the EU.
At national level
Legal developments in the field of drugs in the reporting
period comprise mainly measures towards drug users,
driving under the influence of drugs, and substitution
treatment.
Legal approaches towards (drugs and) drug users
There has been a trend over the year 2001 for some EU
Member States to propose and enact legal changes
directed at distinguishing more clearly drug users from
other drug law offenders and at distinguishing cannabis
from other illicit substances. Countries are considering
various options, which may include a more specialised
court system or a change in the law or policy regarding
drug users. 
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(36) For the latest news and information on developments in Member States’ legal systems on drugs, see the European Legal Database
on Drugs (http://eldd.emcdda.eu.int/).
This is prominent in Portugal, which has removed the of-
fences of drug use, acquisition and possession for personal
use from the status of criminal law, and instead sanctions
these offences administratively through the commissions
for the dissuasion of drug abuse, established in July 2001.
The commissions are composed of three members (ap-
pointed by the Ministries of Justice and Health and the
member of government responsible for the area of drug
abuse), a technical team of three to five professionals (psy-
chologists, social workers and legal experts) and adminis-
trative staff. Cases are assessed individually, and reports by
the technical team support the members’ decisions for
procedures and/or sanctions necessary. In April 2001,
Luxembourg reduced the penalties for cannabis-related
offences, by removing the option of a prison sentence for
possession for personal use and personal use itself, and
declared a prosecution policy aiming to concentrate only
on problematic use. The political note released by the Bel-
gian Government on 19 January 2001 outlines a similar
idea. Luxembourg and Belgium have also used the law to
make a distinction between cannabis and other sub-
stances for the first time, as does a cross-party draft of an
amendment to the drug law in Greece that was put to the
Greek Parliament in April 2001; though this was eventu-
ally rejected by the Greek Parliament in May 2002. In the
United Kingdom, a reclassification of cannabis from class
B drugs to class C drugs (moving possession for use from
an arrestable to a non-arrestable offence) is expected in
2002. In Ireland, non-violent drug addict offenders will be
directed to a drug court that was established on a pilot ba-
sis in January 2001 in Dublin — a similar project was
launched in Glasgow, Scotland, in November. For those
eligible for imprisonment not exceeding six months, the
Dutch Government’s new law on alternative sanctions
came into force on 1 February 2001, permitting the impo-
sition of combined work and educational penalties to-
gether with or instead of prison and/or fines.
However, this trend is not universal; in Finland, an
amendment to the Penal Code in the summer of 2001
removed the right to waive prosecution of drug crimes, if
the offence was considered not detrimental to the obedi-
ence of law, and enabled the prosecutor to conduct sum-
mary proceedings outside court, with a penalty of a fine
or up to six months’ imprisonment. Nevertheless, provi-
sions remain that permit the waiving of prosecution or
punishment if the offence is considered insignificant.
Drugs and driving
There is increasing activity in the field of legislation gov-
erning driving under the influence of drugs, at both pol-
icy and operational levels.
At policy level, in June 2001, the Finnish working group
appointed to implement the new government resolution
on road safety proposed zero tolerance for drugs in road
traffic. Other Member States have strengthened their
regulations regarding who to test and how. In Austria, at
the time of amending the Road Traffic Act in spring
2001, the decision was made to exclude a provision on
obligatory drug tests for drivers. In Portugal in May and
France in November, legislation was put in place for test-
ing individuals involved in traffic accidents, in order to
conduct research on drugs and driving so as to study the
level and type of drug use among drivers and their con-
tribution to accidents and to design a specific and effec-
tive law to address driving under the influence of drugs.
The UK Government also implemented legislation, in
March 2001, regulating the testing and related pro-
cedures on individuals suspected of driving under the
influence of illicit substances.
Substitution treatment
Member States are continuing to work on legislation
regarding substitution treatment for addiction. Some
countries are considering it, and those who have imple-
mented it are improving their legal frameworks.
In Belgium, following the political note of January 2001,
legislation is under preparation to control substitution
treatment. In July 2001, Germany established a central
substitution register, in order to avoid repeated prescrip-
tions of substitution medicaments, and specified an addi-
tional qualification for doctors practising substitution. In
Luxembourg, following a Grand Ducal decree of Febru-
ary 2002, medical doctors prescribing substitution drugs
have to be granted a State licence by the Minister for
Health. The same decree foresees the creation of a spe-
cial surveillance commission and the setting up of a
national substitution register. In Greece, in the frame-
work established by Law 2716/1999, further steps are
planned to strengthen the structure of substitution treat-
ment by expanding the administration of substitutes
through the national health system. Meanwhile, in the
United Kingdom, there is now a legal mechanism (in
place since April 2001) for prescribing buprenorphine
for substitution treatment when previously only
methadone could be prescribed.
Demand reduction
As described above, most EU Member States have a
national drug strategy or similar arrangements (37), as
does Norway, and all include priorities in the field of
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(37) Table 4 OL: Introduction to demand-reduction responses in the EU Member States and Norway (online version).
responses, with some countries (Spain, Ireland, Portugal
and the United Kingdom) having set quantitative targets. 
Naturally, national strategies include a comprehensive
range of responses. However, tentatively, some priorities
can be discerned either to reinforce certain types of
responses and/or to develop more efficient structures (38).
School prevention is seen as a priority in 10 Member
States, whereas importance is given to community pre-
vention in seven. Prevention and early intervention for
young people at risk is high on the agenda in nine coun-
tries. Harm reduction and medically assisted treatment
are each considered a priority in six Member States,
whereas Italy and Sweden put increased emphasis on
drug-free treatment. Seven countries mention responses
in the criminal-justice system as high priorities and six
social reintegration. Eight countries see a need to
improve the treatment structure and four to strengthen
prevention structures in the country.
In most countries, the implementation of demand-reduc-
tion responses is decentralised due to the nature of the
activities. Nevertheless, the priorities set in the national
strategies and the associated funding for research and
practice are essential for realisation at regional or local
levels. The relative importance of policy, practice and
research in implementing responses differs between
countries. Evidently, all influence each other reciprocal-
ly but, in some countries, national policy seems to have
a greater influence on practice while in others, often at
regional level, practice influences policy.
The quality of demand-reduction responses is assured
with the introduction (in some countries) of national
standards, accreditation procedures or guidelines. Treat-
ment has to adhere to quality standards in more coun-
tries than prevention does (39).
Prevention in schools, local settings 
and the community 
All Member States stress the high priority of prevention in
their national strategies and in the numerous preventive ac-
tivities in different settings, most notably in schools. How-
ever, in many Member States, it is becoming increasingly
obvious that there is a substantial gap between policy aims
and the reality and the quality of prevention (40). The real
extent of prevention (e.g. in schools) can be measured ap-
proximately if it is done in a structured way through clearly
defined programmes (41). Only then can key parameters be
assessed — parameters such as content (models and risk
factors addressed) and the number of schools, pupils and
teachers covered. This is the case in some Member States
(Flemish Community of Belgium, Germany, Greece, Spain,
Ireland and the United Kingdom) where programme-based
information is available and can be evaluated. However,
often the prevention of addiction is embedded into broader
school policies with the aim of enhancing healthy lifestyles
in daily (school) life. In this ‘unstructured’ context, preven-
tion is carried out ad hoc through local advisory groups or
councils (in Denmark, France and Norway), and/or is
closely related to specific needs emerging and to resources
(e.g. in France, Italy, Austria, Portugal and Finland). How-
ever, this approach is hard to capture in a standardised way
and difficult to evaluate.
The range of objectives in school prevention is wide:
besides the frequent mention of all-inclusive health pro-
motion principles, the scope ranges from development of
social/personal skills to the promotion of identity/person-
ality. Awareness and information are often at the core of
drug prevention, although such approaches alone have
proven ineffective (Skolverket, 2000). There is no com-
mon European, evidence/research-based prevention
principle in this field. The transnational ‘Healthy school
and drugs’ project, financed by the European Commis-
sion, applies evidence-based quality elements in school
prevention (http://www.school-and-drugs.org).
Another key problem is the logistical and administrative
step of implementing the good practice model pro-
grammes (including evaluation) on a large scale within a
country. Germany and the Netherlands explicitly refer to
this challenge. Attention to prevention in some Member
States (e.g. in Denmark and Germany) is experiencing a
recent shift towards recreational settings in response to
changing consumption trends and is moving in terms of
content from risk avoidance to risk management. A Euro-
pean web site (http://www.drug-prevention.de) gathers
projects that operate according to this philosophy. Over-
all, web sites for preventive purposes have increased in
number and attractiveness in most Member States (42).
Another additional element is a set of guidelines on how
to identify and deal with pupils that are taking drugs.
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(38) Table 5 OL: Overview of the demand-reduction priorities in the Member States and Norway (online version).
(39) Table 6 OL: Overview of quality standards for prevention and treatment in the Member States and Norway (online version).
(40) Table 7 OL: An overview of prevention objectives, school programmes, web sites and prevention activities organised in recre-
ational settings (online version).
(41) An overview of prevention programmes in schools is provided online in Table 7 OL (School programmes) (online version). 
(42) A list of prevention web sites is provided online in Table 7 OL (Web sites) (online version). 
A recent growing interest and allocation of resources to
quality assurance and evidence-based prevention can be
clearly noticed in some Member States (Spain, Ireland, the
Netherlands and the United Kingdom). As a parallel devel-
opment, Germany, Greece, France, Ireland, the Nether-
lands and the United Kingdom are setting up databases to
assess and monitor their national ‘prevention coverage’.
Spain already has an established information system.
As far as community programmes are concerned, there is
no common concept among Member States. To begin
with, this activity is not limited to prevention only:
reduction of drug-related risks is often also included in
community programmes. Besides, ‘community pro-
gramme’ in some Member States means a programme
carried out in a community (i.e. top-down), in others a
programme carried out by a community (i.e. bottom-up).
Wide disparities also exist between Member States con-
cerning the role of mass media in prevention strategies —
from none at all (in Austria and the United Kingdom) to
very prominent (in France and Italy). Peer-group ap-
proaches are strongly contested as well; they are exten-
sively used in the Flemish Community (De Sleutel) of Bel-
gium and in Denmark (Guardian Angels), while in some
Austrian provinces they are rejected as being ineffective.
Prevention in recreational settings
From a conceptual point of view, prevention in recre-
ational settings can be seen as the overlap zone between
prevention and risk reduction and thus often embraces
conflicting ideological factions. In some Member States,
the projects see themselves as ‘secondary prevention’,
while others seek to conceptualise their work as ‘harm
reduction’. In broad terms, this form of prevention is
based on three intervention strategies: the production of
information material on drugs and the health, legal and
emotional issues related to them; related personalised
interventions in discotheques or raves; and structural
measures such as safe-clubbing guidelines (43).
Producing and distributing information material is tradi-
tionally the preferred and most widespread activity in
recreational settings. In Germany, Spain and the United
Kingdom particularly, numerous leaflets, posters and fly-
ers are produced by diverse actors, but little is known
about the impact of these unidirectional and anonymous
communication strategies.
In fewer countries (Germany, Spain, the Netherlands and
the United Kingdom), peer-group approaches are applied
to reach clubbers in order to transmit preventive infor-
mation in a more interactive and personal way, still
using information material as handouts.
The importance and impact of simple but basic rules for
safety in party settings has become increasingly recog-
nised. These means of structural prevention, already
available in the United Kingdom as official safer dan-
cing guidelines (http://www.clubhealth.org.uk/pages/
downloads.htm), are the most direct way of preventing
drug-related problems in party settings. They aim to
assure that the most frequent health hazards are min-
imised through the provision of fresh drinking water and
chill-out areas to avoid overheating, through the training
of staff in first aid and monitoring and in the detection of
early problems through facilitating the work of outreach
teams for prevention. These guidelines exist in several
countries but their implementation by club owners or by
the responsible local authorities in Member States is still
very irregular. There are, however, initiatives to have a
harmonised set of safe-clubbing guidelines Europe-wide.
More infrequently, for example in Belgium and Ger-
many, specific interventions are offered, such as the
management of ‘bad trips’ — that is how to deal with the
adverse and unexpected effects of drugs without resort-
ing to hospitalisation — and, in some Member States, the
analysis of pills at festivities.
The value of on-site pill testing interventions for selectively
attracting a target group of experienced or experimenting
party-drug users for intense interactive preventive coun-
selling (44) has been overshadowed by discussions focusing
on questions of its pharmacological accuracy (Winstock et
al., 2001) and its ideological (45) or legal implications.
Prevention of infectious diseases
Major evidence-based responses to prevent infectious
diseases among drug users are community-based out-
reach, drug treatment — in particular the prescription of
methadone or other substitution drugs (which has
expanded considerably in the EU and Norway over
recent years, see the section on ‘Treatment’) — hepatitis
immunisation, access to sterile injection equipment and
safer use information and training (46).
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(43) An overview of prevention initiatives in recreational settings is provided in Table 7 OL (Recreational settings) (online version).
(44) See the EMCDDA study (http://www.emcdda.eu.int/multimedia/project_reports/responses/pill_testing_report.pdf), pp. 35–37.
(45) Article in Corriere della Sera, 2 November 2001.
(46) See also: Drugs in focus, Briefing 4, EMCDDA, Office for Official Publications of the European Communities, 2002. 
Some outreach services are available in all EU countries
and Norway, but the degree to which staff of drugs agen-
cies set off and bring their services to where the clients
are varies considerably between and within countries.
Low-threshold services remain an important access point
to inform and educate drug users about the risks of use
and how to reduce them. Their role in providing basic
health care services to drug users that can contribute to
reducing the risk of acquiring infectious diseases is
increasingly recognised and low-threshold services have
been further expanded in several EU countries and Nor-
way in 2000.
Special programmes that provide access to sterile inject-
ing equipment are of major importance for minimising
the rate of HIV and other blood-borne viral infections in
drug users; and syringe exchange programmes (SEPs),
through drugs agencies and pharmacies, or vending
machines exist in all EU countries and Norway. SEPs
have been expanding in 2000 (47). Large differences in
availability and coverage between and within countries
still remain (Wiessing et al., 2001).
In Helsinki and several other Finnish municipalities,
injecting equipment has become more available in
2001. In the Flemish Community of Belgium, the first
needle exchange was opened at the end of 2000 — six
years after the first such service was available in the
French Community. The Irish national drugs strategy
2001–08 includes risk reduction as part of its treatment
pillar; and the Portuguese national drug action plan Hor-
izonte 2004 has ambitious harm-reduction objectives,
for example the expansion of needle exchanges to all
districts by 2004. However, only 5 % of the available
budget in Portugal has been allocated to the reduction of
drug-related harm and 95 % to prevention, treatment
and rehabilitation. The UK Department of Health
launched the campaign ‘Making harm reduction work’ in
England, to encourage and develop harm reduction with
drug users (Hunt et al., 2001).
The impact of harm-reduction policies on the hepatitis C
epidemic was explored in research studies in England
and Wales (Hope et al., 2001) and in Ireland (Smyth et
al., 1999), and indications of reduced risk behaviour as a
consequence of such strategies have been found.
Systematic efforts are under way in Germany, Ireland,
the Netherlands, Portugal, Austria, Finland, the United
Kingdom and Norway to make hepatitis B vaccination
more accessible and achieve full immunisation among a
higher percentage of drug users. Currently, the vaccina-
tion does not seem very accessible to drug users and im-
munisation rates are low in general. Costs might also
play a role — for example, in the Flemish Community of
Belgium, drug users are not a priority group within the
Ministry of Health’s immunisation policy, and conse-
quently, the vaccination is not free (48).
Prevention of drug-related deaths
In 2000, an estimated number of 7 000 to 8 000 drug-
related deaths due to accidental or intentional overdose
were recorded in the EU. Research has shown an
increased risk for drug injectors, and in particular for
those who combine heroin with central nervous system
depressants such as alcohol or benzodiazepines (see the
‘Drug-related deaths’ section).
Scientific evidence indicates that methadone maintenance
has a substantial protective effect on mortality from opioid
overdose and mortality from all causes (WHO, 1998). Inno-
vative approaches to preventing and managing overdoses
— such as the training of drug users to protect themselves
against overdosing and to better manage overdoses they
witness, naloxone administration training as well as basic
resuscitation techniques, or the development of specific
prevention information materials — are reported from Bel-
gium, Germany, Finland, Norway and the United Kingdom.
In the latter, the government launched an action plan to pre-
vent drug-related deaths in November 2001, which in-
cludes training and information campaigns, as well as mon-
itoring and research activities (49).
Availability of treatment facilities
The past five years have seen a considerable increase in
the availability of treatment facilities in the European
Union and Norway (50). The provision of both medically
assisted treatment (substitution treatment) and drug-free
treatment has increased, although the degree of increase
varies largely between countries. 
On the whole, medically assisted treatment appears to
have grown more rapidly than drug-free treatment. Rapid
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(47) Table 8 OL: Provision and types of syringe exchange programmes (SEPs), pharmacy involvement, number of syringes distribut-
ed/sold (online version). 
(48) Table 9 OL: Provision of HIV counselling and testing, HIV treatment and HBV vaccination for injecting drug users (IDUs) in some
European countries, as reported by national focal points, 2000 and 2001 (online version).
(49) Examples of overdose prevention messages used in the campaign are available online (online version). 
(50) Table 10: Availability of drug-free treatment in the European Union plus Norway (in units) and Table 11 OL: Substitution treat-
ment amongst problem drug users (in number of persons) (online version).
increases in medically assisted treatment have taken
place in France (from 500 to more than 78 000 clients 
in the period 1993–2000), Norway (from 50 to 1 100
clients in the period 1997–2001), Finland (from 10 
to 240 clients in the period 1996–2001) and Spain (from
12 000 to 72 000 clients in the period 1993–99). Drug-
free treatment slots are not recorded in the same system-
atic and quantitative manner but they rose, for example,
in Denmark (from one specialised drug therapeutic com-
munity in 1994 to around 35 in 1999) and in Greece
(from one specialised drug therapeutic community in
1983 to eight in 1999).
The increase in treatment facilities is not only welcome
but needed to tackle the problem of drug addiction in
Europe. However, there are still reports from Greece and
Portugal, for example, that the supply of treatment does
not meet the demands of clients, and research on a sys-
tematic matching of clients to treatment has not been
very conclusive. These crucial matters must be dealt
with in order to improve the responses to drug addiction
and to improve treatment outcomes (51).
Criminal-justice responses
Judicial authorities in EU countries dispose of a range of
measures at different stages of the criminal-justice system
to divert into treatment drug users who have committed
a criminal offence (52). An increasing effort among Mem-
ber States can be noted to better document the available
range of measures, to map their level of application and
to evaluate their efficiency. These initiatives are relevant
for the assessment of progress with regard to Target 5 of
the European Union drugs strategy — ‘to reduce sub-
stantially over five years the number of drug-related
crimes’ — insofar as alternative measures are ultimately
aimed at a reduction in criminal recidivism and relapse
into drug use among drug-using offenders. Some ex-
amples are given below.
Referral to treatment
Arrest-referral schemes and ‘drug treatment and testing
order schemes’ (DTTOs) have been found useful in the
United Kingdom to increase the number of drug-using
offenders in treatment. Research has demonstrated that
the crisis of arrest is an important opportunity to target
drug-misusing offenders with prevention and treatment
services (DPAS, 2000) and it is planned to extend the
schemes to all police forces in the country by May 2002.
The first evaluation of DTTOs (carried out 18 months
after they were set up) found a reduction in the amount
of money spent on drugs and of the number of offences
committed (Turnbull and Sweeney, 2000) and they were
subsequently introduced in October 2000 after the suc-
cessful pilot phase.
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By September 2001, there were 19 consumption rooms
in Germany (Stöver, 2002); over 20 official drug con-
sumption facilities operated in 2002 in several Dutch
cities. Spain opened an injection room in May 2000 in
Las Barranquillas, near Madrid and a mobile injection
facility has been operating in Barcelona since 2001.
Facilities for supervised drug use are part of the Por-
tuguese harm-reduction policy framework and foreseen
within the national drug action plan Horizonte 2004. In
Luxembourg, legal obstacles were removed for injecting
rooms to be considered as drug care services and it is
planned to integrate an injecting room into the expand-
ed services of an ‘emergency shelter centre’ by 2003.
In Norway, the outgoing government suggested (in
autumn 2001) that a trial be conducted, preceded by a
public hearing. The current government decided in May
2002 against the trial, supported by the majority of
replies to the hearing. An injection-room initiative in
Denmark was shelved by the Ministry of Health in 2000
as a result of international conventions dealing with this
matter. A survey in Austria (Feistritzer, 2001), where the
establishment of a drug consumption facility (health
room) has been discussed for several years, showed
more favourable attitudes among the general public
towards injection rooms in 2001 (28 %) than in 1997
(20 %).
Objectives, services provided and the utilisation of con-
sumption rooms have been described in several studies,
which ‘… provide some evidence in relation to the four
main expected benefits of such facilities: reduced public
nuisance; improved access and uptake of health and
other welfare services; reduced opioid-related overdose
risk; and reduced risk of blood-borne virus transmission’
(Dolan et al., 2000). The EMCDDA is currently preparing
a summary of the experiences, challenges and lessons
learned from drug consumption facilities.
Drug consumption facilities
(51) Successful treatment is one of the selected issues covered in Chapter 3 of this report.
(52) See also: Drugs in focus, Briefing 2, EMCDDA Office for Official Publications of the European Communities, 2002.
An experimental four-year project on treatment for local
criminal addicts conducted in The Hague (Netherlands),
consisting of detoxification and aftercare, showed an en-
couraging level of 40 % of programme participants ab-
staining from drug use in the two years following the inter-
vention but also a high interrelation of positive outcomes
to continuous treatment (Vermeulen et al., 1999). An eval-
uation of the treatment order policy injonction thérapeu-
tique in France (Setbon et al., 2000) showed, however, a
lack of effectiveness. A drug court, which provides a
scheme for the rehabilitation and structured supervision of
persons who committed minor drug offences, was estab-
lished in Ireland in January 2001 on a pilot basis. It should
be noted, however, that so far neither the DTTOs in the UK
or the Irish drug court have been subject to a more rigor-
ous evaluation, using randomised controlled trials.
Treatment in prison
This item is covered in Chapter 3 of this report in the
selected issue ‘Drug use in prison’ (page 46).
Probation
Release on probation is a measure that is available under
certain conditions to convicted offenders in all EU coun-
tries, but some jurisdictions define special conditions for
drug users. Attempts to analyse the outcome of these
alternative measures are still very scarce. However, in
Italy, an analysis of the revocation of probation awarded
to drug-using offenders found low rates: of a sample of
4 237 drug users under probation supervision in the first
half of 2000, only 253 (6 %) had their sentence revoked
and were sent to prison.
Further evaluation studies of referral to care instead of pun-
ishment (Finland), treatment in the correctional system
(Sweden), treatment of criminal addicts outside prisons
(Denmark), and forensic addiction care (the Netherlands)
are still under way. Luxembourg’s new global drug care pro-
gramme will have an important evaluation component right
from its start in mid-2002. All prison-based treatment pro-
grammes in the United Kingdom are currently in the process
of quality evaluation to obtain their official accreditation.
A literature survey about the effectiveness of judicial
sanction programmes in general (Beenakkers, 2000),
commissioned by the Dutch Ministry of the Interior, con-
cluded that effectiveness depends on adjacent interven-
tions or treatments, and advises the use of cognitive-
behavioural approaches and ‘stepped care’ arrangements
to reduce recidivism. The latter finding was confirmed
by further specific reviews carried out in the Netherlands
in 1998 and 1999, which focused on measures directed
at drug-using offenders.
Supply reduction
Drug production and drug trafficking in the European
Union 2000/01 remain the primary activities of criminal
groups in the EU (Europol, 2001). These groups are 
taking full advantage of the opportunities created by a
globalising market economy, including the use of mod-
ern technologies. They tend to be engaged in more than
one type of crime, not limiting their activities to one sin-
gle type of drug, as reflected by the increasing number of
polydrug seizures.
Combating organised drug trafficking is a priority for
Member States. An effort to improve database systems
and crime analysis techniques, together with the assign-
ment of additional resources, is taking place in several
Member States. At the same time there is increased
development of international cooperation, involving
some international organisations as well as Interpol and
the World Customs Organisation (WCO).
Increased international cooperation is resulting in the
establishment of specific task forces, such as the one cre-
ated with a view to pooling and processing all informa-
tion regarding drug trafficking along the Silk Route, cur-
rently involving Interpol, Europol, the World Customs
Organisation and the German Bundeskriminalamt (BKA).
Under this scheme, the BKA is carrying out analyses
based on information provided by other members of the
task force. Another example is ‘Operation Road Runner
II’, funded by the European Commission, aiming at
surveillance action to combat drug trafficking along the
Balkan route. This has resulted in the seizure of signifi-
cant amounts of drugs, with the participation of the 15
EU Member States and 13 central and east European
countries (see http://www.europol.eu.int).
Fighting against the diversion of chemical products and
precursors under control is an important part of the
increased international cooperation. It is believed that
1 500 tonnes of acetic anhydride out of an annual 
global production of 2.5 million tonnes are being diverted
for heroin processing. About 20 % of the global output of
acetic anhydride is produced in the European Union.
‘Operation Topaz’, an action against the diversion of
acetic anhydride includes a system aimed at identifying
the origin of seized chemicals. This operation has
enabled the intervention of 11 shipments with almost
230 tonnes of acetic anhydride which could have been
used in the production of between 55 and 230 tonnes of
heroin. The volume of international legal trade repre-
sented some 180 000 tonnes in 2001. As most of the
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shipments do not go directly from producer to consumer
countries, additional resources to guarantee an adequate
level of surveillance are required. The INCB (Internation-
al Narcotics Control Board) has noticed that some key
national authorities, such as the Dutch ones, which con-
trol a large proportion of transit operations, have signifi-
cantly increased their resources for this purpose (see
http://www.undcp.org).
The international surveillance programme concerning
potassium permanganate has led to the confiscation of
1 100 tonnes of this chemical. Surveillance programmes
concerning potassium permanganate have led to a situa-
tion in which export notifications from the main export-
ing countries have to be communicated beforehand.
‘Operation Purple’, which started in 2000, continued to
increase its results during 2001, with 17 shipments to the
illicit market stopped, representing 1 100 chemical
tonnes. In 2000, 13 shipments were stopped and some
655 tonnes were seized. The volume of international
legal trade relating to potassium permanganate during
2001 represents some 19 000 tonnes. The volume in
2000 was 11 000 tonnes. This programme has also
allowed new methods and new routeing concerning the
diversion of this chemical to be identified, without
imposing undue delays to licit international trade. How-
ever, the INCB has noticed a constant increase in the
number and the volume of shipments towards countries
not participating in ‘Operation Purple’ (see the INCB
2001 report on precursors (http://www.undcp.org)).
International customs cooperation and the activities of the
OECD Financial Action Task Force (FATF) play a very im-
portant role in measures against money laundering. In
November 2000, the United Nations Convention against
Organised Transborder Criminality acknowledged the im-
portance of measures concerning detection and surveil-
lance of the flow of transborder cash and bonds. The im-
portance of cash flows related to drug trafficking has been
acknowledged by international organisations cooperating
against money laundering (see the FATF report 2001/02
(http://www.oecd.org/FATF)). One example of the signifi-
cance of regional cooperation is ‘Operation Goldfinger’,
involving customs authorities in the Baltic region, devoted
to collecting information relating to operations of more
than USD 10 000. The main conclusions to be drawn from
this operation are the deterrent effect that regional cus-
toms cooperation has on money-laundering activities and
the great divergences that exist in national legislation con-
cerning cash flows (see the 2000 customs and drugs report
(http://www.wcoomd.org)).
The main FATF activities have been related to spreading
the message of anti-money-laundering to all continents
and regions of the globe, to improve members’ implemen-
tations of the 40 FATF recommendations adopted in 1990
and modified in 1996, and to strengthen the review of
money-laundering methods and counter-measures. In
June 2000, the FATF began its non-cooperative countries
and territories exercise (NCCT), aiming to identify the
countries and jurisdiction that do not meet the FATF anti-
money-laundering criteria. The FATF has also fostered the
creation and strengthening of FATF regional-style bodies.
The annual survey of money-laundering typologies,
chaired by Norway in 2001, focused on a number of ma-
jor issues such as: online banking and Internet casinos;
trusts; non-corporate vehicles and money laundering;
lawyers, notaries, accountants and other professionals; the
role of cash in money-laundering schemes; and terrorist-
related money laundering. Finally, the European Central
Bank and Europol were granted observer status within the
FATF (see http://www.oecd.org/FATF).
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they include medical drugs prescribed to drug users in
treatment (in Germany, France, Ireland and the United
Kingdom).
Health risks
The combinations of drugs identified in mortality and
overdoses provide indications of particular risks associat-
ed with drug combinations (see box below).
Health risks associated with combinations of psycho-
tropic substances depend not only on the pharmacologi-
cal properties and amounts of the substances consumed
but also on a range of individual characteristics and
social and environmental factors.
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Polydrug use
The broad definition of ‘polydrug’ used by many Mem-
ber States is the use of more than one drug or type of
drug by an individual — consumed at the same time or
sequentially (as defined in the WHO lexicon). In Europe,
the concept of polydrug use dates back to the 1970s. In
its broadest terms, polydrug use is defined as the use of
an illegal drug plus another legal or illegal drug. Howev-
er, considerable differences exist in the substances
included and in the time frames employed by different
Member States. Differences appear to depend on the sur-
vey data available and on the perceptions of risk associ-
ated with particular substances or combinations. The
substances included are usually the main illegal drugs,
alcohol and medicines. Energy drinks are sometimes
included and France includes tobacco. Time frames for
consumption range from a six-hour period to ever expe-
rienced during an individual’s lifetime.
According to the broad definition, all illegal drug users
would be defined as polydrug users as they almost
always use alcohol and/or tobacco at some time in their
life. Even when polydrug use is defined according to the
more narrow range of ‘illegal drugs’, the combinations
and patterns of use vary so much that there is little value
in adopting a standard definition. For the purposes of
addressing general concerns about polydrug use in the
EU, we take acute risks for health as a main focus. 
There is general consensus that polydrug use has four
main functions: it maximises effects, balances or controls
negative effects and substitutes sought after effects. Infor-
mation about the functions of combining particular drugs
is based on descriptions by users of attempts to have, and
prolong, pleasurable experiences (Seppälä, 1999; Strang
et al., 1993). The substances that are used depend on local
availability, fashion and local prescribing practices where
3
• Whilst it is difficult to overdose on benzodiazepines
alone, the combination of a large dose of benzodi-
azepines and a large dose of alcohol or an opiate
drug such as heroin or methadone may be fatal.
• When ecstasy is used with alcohol, health risks
increase because alcohol impairs thermal regulation
and increases dehydration.
• When cocaine is combined with alcohol, the combi-
nation may be more directly toxic to the heart and
liver than either cocaine or alcohol alone. Alcohol is
often present in cocaine cardiac deaths. 
• The combined use of different stimulants, including
energy drinks, can lead to sympathetic hyperactivity
that may result in impaired thermal regulation and
cardiac functioning.
Sources: Leccese et al. (2000), DrugScope (2001).
Examples of drug combinations 
considered high risk
This chapter highlights three specific issues relating to the drug problem in Europe:
polydrug use, successful treatment and drug use in prison.
In the context of ‘early-warning systems’, there is grow-
ing concern about the potential mixture of psychoactive
substances in tablets sold as ecstasy, which, despite the
lack of intention on the part of users, may constitute
polydrug health risks. For example, in Denmark during
2001 a range of 10 to 32 % of tablets analysed con-
tained more than one active substance. These tablets pri-
marily contained MDMA and PMA, PMMA, MDE and
MDA. In France, two thirds of an analysed sample of
tablets sold as ecstasy contained MDMA combined with
other active ingredients — mostly medicaments. 
Fatal and non-fatal overdose
During the last decade, press attention on drug deaths
has focused mainly on rare cases of ecstasy death (Bel-
gium, Denmark, Italy and the United Kingdom). Press
interest is not generally captured by the death of prob-
lem drug users. The large proportion of the 7 000 to
8 000 acute drug deaths (overdoses) recorded in the EU
each year are males who have been using opiates for
several years (see the ‘Drug-related deaths’ section). 
Results of toxicological analyses of fatal and non-fatal
overdoses associated (53) with illegal drug use are not
widely available but those that are consistently reveal
that most of the deaths are associated with the injecting
of heroin combined with other drugs. A recent study of
153 drug users in the United Kingdom who had experi-
enced non-fatal overdose found that more than one drug
had been used in 111 (73 %) of cases (Neale 2001). In
fatal overdoses, at least one other drug or alcohol is
involved in over 50 % of cases in the United Kingdom
and up to 90 % in Ireland. Benzodiazepines, alcohol,
methadone and cocaine are the substances most fre-
quently found combined with opiates and a common
explanation for the overdose in question is that these
combinations caused it (ONS, 2000a and b; Farrell,
1989; Bennet and Higgins, 1999; Strang et al., 1999;
Taylor et al., 1996) (54). 
Deaths associated with cocaine, amphetamine or
MDMA (ecstasy) without the presence of opiates or ben-
zodiazapines are infrequent and are usually combined
with other drugs or alcohol. 
Other risks
Polydrug use is also considered to be a particularly high
risk for dangerous driving but EU data on drugs and driv-
ing is very limited. Violent or aggressive behaviour has
recently been associated with patterns of increased use
of alcohol combined with stimulant drugs (Snippe and
Bieleman, 1997; Vermaas, 1999). 
Trends
In some countries, the number of fatalities that constitute
the most serious consequences of polydrug use are still
increasing. The substances detected most often were
combinations of morphine, benzodiazapine and alcohol,
with recent national or local increases in cocaine report-
ed in Spain, France, Italy, the Netherlands and the Unit-
ed Kingdom (see the ‘Drug-related deaths’ section for
more details). 
Concern about groups at risk
Social and public concern associated with patterns of
polydrug use generally focuses on two groups that are
distinct with regard to the type of substances and combi-
nations they use and the environments where their con-
sumption occurs. 
• The greatest scientifically evidenced health risk
occurs among problem drug users, particularly those
who inject opiates and other drugs.
• Media and general public concern also exists about
the risk of death and overdose for recreational drug
users who are not addicts and whose consumption of
illegal drugs is mostly limited to specific social set-
tings or a certain phase in their lives. This concern is
disproportionate in view of the relatively limited
number of deaths.
For problem users, the number and characteristics of
clients seeking treatment in the specialised centres in
Europe are used as an indirect indicator. For recreational
drug users, the results of a large European survey of
recreational drug users in nine European cities and a
number of ad hoc ‘clubbers’ surveys are available.
Problem drug users
Since the 1970s, problem drug users have been shown
to adjust the ingredients of their drug menus according
to the availability of drugs on the market and at differ-
ent stages in their lives. They may substitute the un-
available substance with another, not necessarily of the
same type (Haw, 1993; Strang et al., 1993; Fountain et
al., 1999).
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(53) A drug is deemed implicated, or associated, when it is proven positive at toxicology or when evidence was presented that the
drug had been consumed prior to death. This is not to infer that the drug is the cause of death. It may imply the drug(s) as being
a contributory factor in the death.
(54) Table 12 OL provides an example of the number of drugs implicated in opiate deaths in Ireland (online version).
Polydrug use among clients in treatment
At European level, treatment data provide information on
primary and secondary drugs: the primary drug is the
‘drug that causes the client the most problems’ (55) and
the secondary drugs are the next most problematic drugs
after that. The European information system on treat-
ment, based on the Treatment Demand Indicator (TDI)
protocol, which registers up to four substances used by
each person, could be taken as an indirect indication of
problematic polydrug use (56), although it is limited to
users in treatment.
Most clients in treatment use secondary drugs combined
with their main drug (83.2 %) (Figure 23). Many coun-
tries report an increase in polydrug use (57).
The most common patterns of problematic polydrug use
are: heroin combined with other opiates such as diverted
methadone or with benzodiazepines; heroin combined
with cocaine, cannabis and stimulants or alcohol; and co-
caine used with alcohol or stimulants (58).
The patterns of use change markedly among countries
and sexes. The available data show that in some
countries a single pattern prevails, whilst others pre-
sent different drug combinations. From the available
data, homogeneous patterns seem to be found in
some countries, for example, in Greece and Italy for
primary drug distribution, where heroin is used simul-
taneously with hypnotics, sedatives, other opiates or
cannabis. In Spain and the Netherlands, where the
proportion of clients seeking treatment for cocaine as
primary drug is rather high, cocaine also frequently
appears as a secondary drug combined with heroin or
stimulants.
As far as gender distribution is concerned, polydrug
users in treatment are mainly men, especially among
those using heroin combined with opiates and cocaine
or alcohol; a higher proportion of women is found
among those using stimulants with cannabis, stimu-
lants, and other substances (hypnotics/sedatives,
volatiles) (59).
Persons accompanying their main drug with cannabis
are mainly aged between 15 and 24; the polydrug users
of opiates and cocaine are older (20–39) and those who
use other drugs simultaneously with alcohol are the old-
est polydrug users in treatment (60).
From the data available, the following patterns of use
among clients in treatment can be identified:
• older clients, mainly males, using opiates as the main
drug combined with other opiates, or cannabis;
• younger clients, males and females, using cannabis
and stimulants combined with alcohol or other sub-
stances (such as hallucinogens);
• males, under 30, using cocaine combined with alco-
hol and other stimulants; and
• males, 20–39, using heroin and cocaine.
Selected issues
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(55) In the Treatment Demand Indicator standard protocol 2.0, item 14, primary drug is defined as the ‘drug that causes the client the
most problems’ and item 19, other (= secondary) drug in addition to primary drug, as an indication of multiple drug use (see the
web site http://www.emcdda.eu.int/multimedia/project_reports/situation/treatment_indicator_report.pdf).
(56) Countries where data were available on this topic were: Belgium, Spain, Greece, Italy, the Netherlands, Sweden and Finland. 
(57) See Reitox national reports, ‘Treatment demand’ section, Chapter 1, Figure 6, ‘All clients admitted to treatment’.
(58) Figure 16 OL: Common patterns in the combination of drugs: most problematic drug used together with secondary drug(s)
(online version).
(59) Figure 17 OL: Second most problematic drug by gender (% on the total, by drug) (online version).
(60) Figure 18 OL: Second most problematic drug, by age (online version).
Sources: 2000 Treatment Demand Indicator (TDI) data on outpatient treatment centres.
Reitox national reports 2001.
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Recreational drug users
Prevalence of polydrug use is higher among young 
people in dance club settings than among young people
in other settings, particularly the use of alcohol, cannabis
and stimulant drugs (Calafat et al., 1999; ESPAD, 2000).
There is also some evidence that, across Europe in gen-
eral, prevalence of recreational polydrug use is higher
among males and regular users of cannabis than it is
among females and cannabis experimenters, although
there are geographical differences. A large European
study of drug users in targeted nightlife settings in 1998
showed that approximately half of all drug users in the
techno party scene reported that they combined alcohol
and cannabis, followed by alcohol and ecstasy, and
cannabis and ecstasy (Calafat et al., 1999). Table 1
shows that recreational drug use is heavily dominated by
alcohol. The majority of leisure-time drug users do not
consume large quantities of illegal drugs and alcohol in
combination. However, studies suggest that the propor-
tion of people adopting ‘heavy’ patterns of drug use is
increasing and there are growing concerns about the
health risks and potential long-term damage from specif-
ic patterns of recreational drug use (Club Health, 2002;
Hunt, 2002; McElrath and McEvoy, 1999; Reitox).
Heavy polydrug use in leisure-time settings is associated
with repeated exposure to drug availability and positive
images of drug combinations among peers. However,
heavy drug use is generally confined to particular social
events, holiday periods or during particularly social and
outgoing phases in life (Bellis et al., 2000).
An increase in heroin smoking has been reported by
some Member States (France and Italy). In recent years,
there have been particular concerns about people smok-
ing heroin to come down from ecstasy but the evidence
for this is mixed or contradictory. For example, studies in
treatment and prison settings in Ireland report that over
half of the drug users interviewed had smoked heroin to
‘come down’ off ecstasy whilst surveys of recreational
drug users and school students aged 15–16 show that
heroin still has a very negative image (ESPAD, 2000).
Local market
Little research has been conducted on drug markets in
the EU and it is therefore not possible to provide accu-
rate details on the combinations of drugs available on
local markets. 
In terms of ‘marketplaces’, in the United Kingdom there
are regular media reports of ecstasy, amphetamine, co-
caine powder and cannabis dealing in clubs and bars for
the clubbing population. However, research in the
Netherlands has shown that many young clubbers obtain
their drugs via friends rather than dealers. Some of the
marketplaces patronised by those who buy and sell
heroin, crack cocaine and prescription drugs (such as ben-
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%
Drug combinations used by recreational
drug users in the same night 
Table 1
Alcohol and cannabis 50.6
Alcohol and ecstasy 11.9
Alcohol and cannabis and ecstasy 10.4
Cannabis and ecstasy 8.4
Alcohol and cocaine 7.8
Cannabis and ecstasy, alcohol and cocaine 7.8
Cannabis, alcohol and cocaine 2
Source: Calafat et al. (1999).
Sources: 2000 Treatment Demand Indicator (TDI) data on outpatient treatment centres.
Reitox national reports 2001.
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zodiazepines) are well known, but are usually separate
from those for clubbers. Different substances are sold in
different marketplaces: some concentrate on diverted pre-
scription drugs whilst others trade primarily in heroin
and/or crack cocaine. In the case of diverted prescribed
drugs, distribution is conducted by a large number of 
people each selling some or all of their own prescribed
drugs (Edmunds et al., 1996; Fountain et al., 1999).
Polydrug use interventions
Two distinct target groups can be defined for which
interventions are designed: older problem polydrug users
and young recreational drug users.
Older problem polydrug users
In the context of older problem polydrug users, preven-
tion of drug-related harm is of importance due to the pos-
sible unexpected consequences. Interventions include
providing drug users with adequate knowledge on the
effects of specific drugs and the consequences of mul-
tiple drug use and how to handle drug emergencies.
Polydrug use has shown to be more difficult to treat than sin-
gle drug use. Member States do not report specific treatment
programmes for particular drug combinations but nearly all
services are open to polydrug users. The focus is on be-
haviour rather than substances. However, in acute treatment
and in withdrawal, polydrug use might be very relevant.
The combination of heroin and benzodiazepines has
implications for the efficacy of treatment. If opiate use is
being addressed while coexisting benzodiazepine use is
neglected, there is potential for reducing the efficacy of
substitution treatment, for example with methadone. In
the United Kingdom, the official prescribing guidelines
(Department of Health et al., 1999) stress that stimulants
should not be prescribed to polydrug users.
In all countries except Sweden, a considerable problem
consists in getting substances other than opiates under
control in medically assisted treatment, for example with
methadone. In countries other than Sweden, the advan-
tage of having regular contact with drug users in substi-
tution programmes is obviously considered more impor-
tant than the disadvantage of concurrent use of other
drugs. In Sweden, however, polydrug users are not
accepted in methadone treatment irrespective of the seri-
ousness of the heroin problem.
Psychiatric comorbidity is often diagnosed in polydrug
users. Denmark, the Netherlands, Austria, and Sweden
report on a high and possibly increasing number of poly-
drug users admitted to psychiatric hospitals.
There is little research on the effectiveness of the treat-
ment of polydrug users. Generally, the adjustment of
treatment to each specific case contributes to treatment
success. The UK NTORS study found that after one year,
opiate users who were frequent users of stimulants at
intake showed marked improvements in terms of
reduced levels of opiate and stimulant use (Gossop et al,
1998). Greece reports that substitution programmes
claim that the treatment interventions contribute to a
reduction in polydrug use (Kethea — NSPH, 2001).
The development of special treatment programmes for
specific groups such as polydrug users is considered a
need in the German national report, and the United
Kingdom suggests disseminating examples of good prac-
tice. Finland states the need for training, and some activ-
ities to train treatment staff in dealing with polydrug
users are already under way.
Recreational drug users
Some countries (Spain, France and Italy) have launched
broad mass-media campaigns to warn against multiple drug
use in recreational settings. In Italy, the campaign was sup-
ported by local initiatives at major youth events. Specific
substances are not always mentioned and the conse-
quences of use are not clearly spelled out. In other countries
(Belgium, Germany, the Netherlands, Austria and the
United Kingdom) these health warnings and advice are
passed through drug workers or peers and self-help groups.
Pill-testing projects may inform users about dangerous and
unexpected pill contents on site, by magazines and posters
or through the Internet. For example, in autumn 2000, Aus-
trian ChEck iT! found several pills sold as ecstasy containing
PMA/PMMA and immediately put out warnings on site and
through the Internet (Kriener et al., 2001). In November
2001, the Dutch DIMS project, for example, provided a
rapid alert about pills containing PMA.
Treatment for users of several drugs in the recreational
scene is virtually non-existent. One reason could be that
most drug services are only equipped to deal with opiate
and severe dependence problems.
Policy issues
The rituals and social controls polydrug users employ to
achieve the sought-after effects whilst simultaneously
reducing risk need to be studied for better understanding
of the social and environmental circumstances that con-
tribute to risk among different drug-using groups (Boys et
al., 2000; Decorte, 1999; Akram and Galt, 1999). 
Prevention, especially in recreational settings should
include clear guidance and advice on risks involved in
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multiple drug use. More evidence-based knowledge is
needed to ascertain the best possible care for polydrug
users and especially for problem drug users with mental
disorders.
For better understanding of pharmacotoxicological risks
from specific combinations, a priority is for clinicians to
follow up patients with suspected drug intoxications and
to provide evidence-based information about acute and
long-term damage to health.
Successful treatment
In the EU action plan on drugs (2000–04), the third strat-
egy target is ‘to increase substantially the number of suc-
cessfully treated addicts’. No aggregated data exist at
European level to directly measure the level of achieve-
ment of this objective. However, many evaluations have
been carried out across Europe exploring if and what
type of treatment works. Findings on successful treat-
ment are presented here according to the type of treat-
ment intervention: withdrawal treatment, drug-free 
treatment and medically assisted treatment. The success
criteria vary between the different types of treatment and
are also related to social reintegration and rehabilitation
after treatment.
Withdrawal treatment
Withdrawal treatment, or detoxification, is generally con-
sidered the first step in a complete treatment process. This
intervention aims, firstly, at arriving at a stage where the
client is physically drug free and no longer craves for 
illegal drugs and, secondly, at transferring or referring the
client to drug-free treatment. In Sweden and Finland, this
process is a prerequisite for starting methadone treatment.
Evaluations of withdrawal treatment have been carried
out across the Member States and Norway but neverthe-
less, globally, it is the least evaluated type of treatment
intervention. Overall, withdrawal treatment with
medicaments such as Naltrexone, clonidine, lofexidine
and buprenorphine have proved effective in decreasing
withdrawal signs and symptoms, although the effect on
different kinds of withdrawal symptom varies between
medicaments (Greenstein et al., 1997). Methadone is
widely used for treating withdrawal symptoms although
research findings suggest that methadone’s strength lies
in maintenance therapy.
Withdrawal treatment with no use of medicaments, also
known as ‘cold turkey’, exists although its extent is not
really known. Nor are there any reports on the effects
and outcomes of non-medically based withdrawal treat-
ment compared to medically assisted withdrawal treat-
ment. The recently emerged concept of rapid detoxifica-
tion with Naltrexone under full narcosis (sometimes
referred to as ‘turbo withdrawal treatment’) should be
investigated in more depth.
One intervention in Portugal which combined the deliv-
ery of naltrexone and psychotherapy found that after
three months there were notable improvements in socio-
demographic and psychological variables as well as in
risk behaviour (Costa, 2000). An experiment in Germany
detoxified methadone users with naltrexone under full
narcosis. The patients’ satisfaction was fair but as many
as 50 % reported severe discomfort in the first month fol-
lowing the intervention. Six months after discharge one
third of the patients had not consumed hard drugs (Tret-
ter et al., 2001).
Although some withdrawal treatment interventions have
been subject to evaluation, more in-depth knowledge is
needed on the pros and cons of the different modalities
and on which type of withdrawal treatment should be
used for which type of patient.
Drug-free treatment
Drug-free treatment applies physic-social techniques in
its aim for the client to become, first, abstinent and, then,
long-term free of drug craving. The primary success cri-
terion used for drug-free treatment is the completion of
treatment as planned drug free, although others such as
improvements in psychological, social and economic
well-being are also essential. Important ‘spin-off’ effects
are a reduction in crime and risk behaviour as well as an
improvement in the health and general welfare of the
client.
Evaluations of drug-free treatment interventions have
shown that, to a greater or lesser extent, it succeeds in
fulfilling these objectives (Gossop et al., 2001). Evalua-
tion results fluctuate greatly, but generally 30 to 50 % of
clients entering drug-free treatment complete it success-
fully. A Danish study concluded that, depending on the
kind of drug-free treatment interventions, successful
completion rates spanned from 17 to 58 % of the clients
entering treatment (Pedersen, 2000).
Another widely acknowledged notion is that treatment
duration is closely linked to treatment outcome or, in
other words, the longer the time spent in drug-free treat-
ment the better. This idea is backed up by a German
study which suggested that retention rates/duration in
drug-free treatment correlate with its outcomes (Sonntag
and Künzel J., 2000). Some research has tried to identify
the threshold at which successful treatment outcomes
are likely to increase. One study found that clients 
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staying in drug-free inpatient treatment for 90 days
achieved better outcomes — in terms of abstinence from
opiates, stimulants and in the reduction of injecting drug
use — one year after discharge than those who left earli-
er (Gossop et al., 1998). This is confirmed by a Greek
study which found that those clients who left treatment
within the first three months only decreased heroin con-
sumption after discharge by 11 % compared with 76 %
for those who stayed at least a year (Kethea, 2001).
Regarding the issue of long-term effectiveness, an Austri-
an study concluded that a treatment scheme with a focus
on social and psychotherapy interventions markedly
increased the social competence and the subjective sat-
isfaction of the clients, which results in their long-term
stability (Wirth, 2001).
The National Treatment Outcome Research Study (NTORS)
was established in 1994 at the request of the British Minis-
ter of Health to assess the effectiveness of drug misuse treat-
ment services in the United Kingdom. NTORS recruited
1075 clients for the project in 1995 and followed them for
five consecutive years. A random stratified sample of 650
clients was selected and followed in four different treat-
ment modalities: inpatient, residential rehabilitation,
methadone reduction or methadone maintenance. The
main finding of the study is that treated individuals do im-
prove on outcome parameters such as drugs intake, injec-
tion frequency, needle sharing and psychological health.
The total aggregated cohort showed statistically significant
improvements in heroin intake — around 75 % had regu-
lar heroin use at intake compared to around 40 % four to
five years on. Regular use of non-prescribed methadone
had gone down from around 30 % at intake to under 10 %
and needle sharing had decreased from around 20 % at in-
take to around 5 %. Scorings on psychological health also
showed statistically significant improvement between the
state at intake and the state four to five years on.
Drug-free treatment has been evaluated across Europe
applying different methodologies, and substantial
insights have been gained especially over the last
decade. However, there are still areas where further
research is needed to respond to phenomena that have
recently emerged. One example is on the efficiency of
drug-free treatment for predominant cocaine users and
amphetamine users as well as other specific sub-popula-
tions. Furthermore, there are few large-scale studies on
how many remain drug free in a longer-term perspective
after the successful completion of treatment.
Medically assisted treatment
Medically assisted treatment (which includes substitution
treatment) uses agonist or antagonistic medicaments in
its therapy of clients. Agonist medicaments (e.g.
methadone) activate the opiate receptors in the brain
and antagonistic medicaments (e.g. naltrexone) limit or
eliminate the effect of other illicit drugs taken. The aim
of medically assisted treatment can be abstinence but
may also be to maintain the client in long-term medical
treatment. Whether the end goal be to achieve absti-
nence or to reduce the harmful effects of drug addiction,
common interim goals include: reducing the consump-
tion of illegal drugs and the risk of infectious diseases;
improving the mental and physical state of the client;
and reducing drug-related crime.
Methadone maintenance is the most widely diffused type
of medically assisted treatment. As ‘maintenance’
implies, the objective of this type of intervention treat-
ment is not abstinence but to keep the client in main-
tenance treatment thereby reducing criminal activity and
risk behaviour (and consequently the risk of the acquir-
ing infectious diseases), as well as improving health and
social functioning.
Medically assisted treatment has been widely evaluated
across Europe and has generally proved effective in
achieving goals such as reducing the consumption of
illegal drugs, risk behaviour and crime. In particular,
medically assisted treatment interventions with
methadone have been evaluated and found effective in
relation to these goals (Lowinson et al., 1997; EMCDDA,
2000), although buprenorphine has proved effective too.
One structured literature review of buprenorphine trials
found that its main strength was in lowering the risk of
overdosing and lowering the level of parallel illicit drug
use (Berglund et al., 2001). For both methadone and
buprenorphine, sufficient dosages have shown to be
imperative to ensuring positive outcomes.
Despite these apparent ‘successes’, some countries con-
sider that neither methadone nor buprenorphine have suf-
ficiently improved the general welfare of particularly de-
prived street addicts and have sought other alternatives.
In February 2002, the findings of a Dutch randomised
controlled trial with co-prescription of heroin for
methadone clients were published. The target groups of
the intervention were severely addicted, older, heroin
users who had not benefited sufficiently from methadone
maintenance treatment. In order to define this target
group, a predefined set of inclusion and exclusion criteria
were established and subjects were selected from the local
methadone maintenance treatment registration system. A
total of 625 patients treated in six units located around the
Netherlands were selected and randomly divided into an
experimental group and control group. First, the patients
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were divided according to their route of administration,
inhaling or injecting, and then subdivided according to
the intervention — those receiving only methadone and
those receiving a combination of methadone and heroin.
The main finding of the study was that for severely ad-
dicted, older, heroin users methadone plus heroin was
more effective than treatment with methadone alone, irre-
spective of the route of administration. The study further-
more showed that at the end of the trial, 30 % of the clients
in the experimental group no longer met the inclusion cri-
teria (their general condition having improved consider-
ably), whereas it was only 11 % in the control group (van
den Brink et al., 2002).
In Germany, a trial with the prescription of medical heroin
for opiate addicts has been developed and refined over the
past couple of years. The trial which began in spring 2002
will last for three years with seven German cities partici-
pating. The main question to be answered is if and under
which condition the prescription of heroin for an ex-
tremely deprived group of opiate addicts can contribute to
improving their situation in terms of health, social and 
legal aspects. The patients in the trial will be divided ran-
domly into an experimental group and a control group.
These groups will be further divided into two groups receiv-
ing different types of psycho-social intervention — one
group ‘case management’ and the other ‘psycho-educa-
tion’. The study is expected to provide further insights on
psycho-social intervention and its efficiency in the treat-
ment of opioid addiction (http://www.heroinstudie.de/).
In Denmark, an alternative to a heroin project was
launched for 2000–02 with the aim of initiating special
pilot projects for drug addicts in methadone treatment,
involving massive psycho-social activities. The qualita-
tive and quantitative evaluation will study the extent to
which results can be achieved in the form of better
social, health-related and mental functioning, reduction
of drug use, reduction of infectious diseases and crime,
as well as an extension of network relations.
Conclusions and future perspectives
Success depends on the purpose of a given treatment in-
tervention and consequently that success should be as-
sessed in accordance with the pre-established objectives.
There is already a considerable wealth of research that,
when comparing objectives with outcomes, has enabled
insight and knowledge to be gained on the effectiveness
and/or success of various types of treatment.
It is, for instance, an important outcome that retention
rates are crucial for treatment outcomes or ‘success’, but
knowledge needs to be gathered on how to keep clients
in treatment or, in other words, on which elements in
treatment are crucial for increasing the retention rate.
Identifying the ‘active ingredient’ in any kind of treat-
ment is a difficult task and it is essential to improve the
performance of treatment services, thereby improving
treatment outcomes.
However, having the theoretical knowledge and insight
is one thing and implementing it another. An example of
this is the importance of accompanying psycho-social
interventions in medically assisted treatment, which
much research has found to contribute to success but
which nevertheless are still not adequately implemented
in practice.
In recent years, much emphasis has been placed on ex-
panding treatment services and this has to a rather large
extent been achieved. The challenge now is to widen the
fan of treatment services and refine the interventions
themselves, thereby increasing the ‘success’ of these.
Drug use in prison 
The presence of drugs and drug use has fundamentally
changed the prison reality over the past two decades
and, nowadays, all countries in Europe experience major
problems due to drugs and drug-related infectious dis-
eases in prisons.
Drug demand in prison (61)
National routine information on drug use, patterns and
consequences amongst prisoners is rare. Most of the data
available in the EU come from ad hoc studies carried out
at local level amongst a small sample of prisoners. This
makes extrapolations very difficult.
Prevalence of drug users in prison
The prison population can be considered as a high risk
group in terms of drug use. Indeed, compared with the
community, drug users are over-represented in prison.
The proportion of inmates in the EU reporting ever
having used an illicit drug varies according to prisons
and countries between 29 and 86 % (over 50 % in
most studies) (Figure 25). As in the community,
cannabis is the most frequently experienced substance,
but several studies also show high levels of heroin
experience (close to 50 % of the inmates or more in
some cases).
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(61) See also the table: Proportion of drug users among prisoners in the EU (online version).
According to different studies, prisoners reporting more
regular and/or harmful use such as intravenous drug use,
regular use or dependence, represent 6 to 69 % of the
prison population.
Level of drug use within prison
Incarceration does not mean cessation of drug use. Most
drug users tend to stop or reduce their drug use after impris-
onment due to the low availability of illicit drugs. However,
some continue to use drugs, to an even greater extent in
some cases, and others commence once incarcerated.
Drug use within prison is reported by 16 to 54 % of inmates;
regular drug use by 5 to 36 %. Between 0.3 and 34 % of the
prison population have ever injected while incarcerated.
Initiation to drug use and injecting also takes place in
prison. According to several studies in Belgium, Ger-
many, Spain, France, Ireland, Italy, Austria, Portugal and
Sweden between 3 and 26 % of drug users in prison
report their first use of drugs while in prison, while
between 0.4 and 21 % of IDUs in prison started inject-
ing in prison (NR, 2001; WIAD-ORS, 1998).
Health and legal consequences
Risk behaviours
Studies conducted in Belgium, Germany, Greece,
France, Ireland, Luxembourg, Austria and the United
Kingdom (NR, 2001) show that a high proportion of
IDUs in prison share injection equipment. Within prison,
intravenous drug use is often associated with the sharing
of injecting material, and in some cases up to 100 % of
IDUs report sharing behaviours. A Luxembourg study
(NR, 2001) reports that, in 70 % of cases, syringes are
cleaned with water only and, in 22 % of cases, they are
not cleaned. The data available show that sharing injec-
tion equipment in prison is more frequent than in the
community.
A multi-centre study carried out in some prisons in Bel-
gium, Germany, Spain, France, Italy, Portugal and Swe-
den in 1996/97 (WIAD-ORS, 2001) reports more tattoos
and piercings during incarceration among IDUs, com-
pared with non-IDUs. IDUs also report a higher level of
unprotected sexual intercourse in Belgium, Germany,
Portugal and Sweden, but less in other countries.
Infectious diseases
Data on HIV and HCV status among injecting drug users
(IDUs) in prison were provided by Belgium, Germany, Spain
(HCV only), France, Ireland and Luxembourg (NR, 2001).
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NB: Values on the figures have been derived from data provided in surveys or studies carried out in the Member States. The online version of the report gives details of the original data sources. 
(1) (2) See online version for explanation.
Sources: Reitox national focal points; see also online table ‘Proportion of drug users among prisoners in the EU’. 
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Figure 25
The number of women in prison is lower than the num-
ber of men. However, drug use seems to be particularly
acute amongst the female prison population. Where data
are available, they show a higher proportion of drug
users among women in prison — considering last six
months prevalence of drug use in Denmark, last year
and lifetime prevalence of heroin use in Ireland, and
proportion of prisoners with a drug problem and with a
severe drug problem in Sweden.
As regards risk behaviours within prison, studies carried
out in Germany (NR, 2001) and France (WIAD-ORS,
2001) show a higher proportion of prisoners sharing
drugs, sharing injecting material and prostituting them-
selves amongst female drug users, compared to males.
Whereas other studies carried out in Austria (NR, 2001)
and England and Wales (WIAD-ORS, 2001) report more
injecting material sharing amongst male prisoners.
Women drug users in prison
They come from local studies carried out in a few prisons,
and thus are not representative of the national level. The
prevalence of HIV among IDUs varies between 0 and
13 % in the prisons investigated. Levels of HCV positive
status are much higher, between 14 and 100 % among
IDUs according to the prison centre and the country. As in
the community, the prevalence of HIV and HCV is higher
in IDUs than non-IDUs.
Sanctions for drug use/possession
Prisoners caught in possession of illicit drugs are usually
sanctioned and punished under prison regulation. The in-
cident might be reported in the personal file of the pris-
oner. The common sanctions applied include restriction of
rights (visits from friends or family, telephone calls), depri-
vation of prison leave, expulsion from specialised treat-
ment wings and/or punishment in an isolation cell.
Possession can have consequences on the execution of
the conviction. For example in Denmark, there is a risk
not to be granted release on parole after having served
two thirds of the sentence. In the United Kingdom, when
a urine test is found to be positive, the sentence can be
lengthened by at least a few extra days.
Prisoners caught with drugs might also be charged and
prosecuted for it out of the realm of the prison.
Drug availability and supply in prison
Availability of drugs
Access to illicit drugs is far more difficult within prison
than in the community. However, illicit drugs are report-
ed to be easily available in prison for those wanting to
use drugs — mostly cannabis, heroin and medicines
(benzodiazepines) — but anything is obtainable in
exchange for payment.
Prisoners report large variations in quality, continuity
and the price of illicit drugs within prison. Prices of
drugs are estimated to be two to four times higher than
outside prison, which makes drugs 10 to 20 times more
expensive in terms of spending power. Payment forms
other than money are extensively used: exchange of ser-
vices (prostitution, cell cleaning) or goods (telephone
cards, tobacco) and/or participation in drug distribution.
Smuggling and trafficking
There are many ways of accessing drugs in prison. All
contacts with the outside world are occasions for smug-
gling drugs into prison: during visits (on visitors’ clothes
or in their body cavities or inside food), transfers or
transportation to court for trial, after prison leave,
through the mail (parcels). Drugs can be thrown inside
balls over the prison walls. They are also smuggled in by
prison staff.
Drug distribution and trafficking varies from one prison
to another and between countries. Belgium reports (NR,
2001) trafficking at individual level as well as pyramidal
networks in which (as in the community) high-level
dealers organise the drug trade but do not use drugs
themselves. Germany mentions (NR, 2001) small-scale
trafficking in which many prisoners are involved through
several channels without central organisation. A study
recently carried out in Mountjoy prison in Ireland (NR,
2001) shows a system based on personal arrangements:
those having access to drugs in the community, smuggle
them into prison and distribute them to their personal
network. Drug trading within prison is reported to be far
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NB: Values on the figures have been derived from data provided in surveys or studies carried out in the Member States. The online version of the report gives details on the original data sources. 
(3) (4) See online version for explanation.
Sources: Reitox national focal points. See also online table ‘Proportion of drug users among prisoners in the EU’.
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Figure 26
more distressing than in the community, leading to
intimidation, bullying and criminality.
To prevent drug smuggling, several measures are imple-
mented — on a routine basis or on suspicion. These
include searches of cells, body searches after prison
leave, interdiction of parcels, monitoring of visits and
placing a net over exercise yards. The United Kingdom
has recently set up measures to reduce supply, such as
increasing the use of dogs to deter and discover smug-
glers and banning visitors caught smuggling drugs into
prison.
Seizures of illicit drugs within prison or at the entrance
are reported by many countries, usually of small quanti-
ties. Drug injection material, chillums and other para-
phernalia are also found during inspections.
Demand-reduction policy in prison
Current demand-reduction measures inside prisons con-
sist predominantly of discouraging drug use through
increased control, such as cell searches and random
drug testing combined with sanctions or loss of privi-
leges. For example, in Sweden, prisoners undergo an
average of two to three urine tests per month.
Confronted with an increasing number of drug users,
prison systems have set up specialised addiction care
units (e.g. in the Netherlands), have centralised drugs
services in specific prisons (Ireland and Austria), or
‘imported’ expertise in addiction care from external
drugs agencies.
Since 1995, an expansion of services for drug users in
prisons has been noted (Ambrosini, 2001) and measures
to prevent the transmission of infectious diseases intro-
duced. Compared to the community, however, there was
a considerable time lag. The current offer of addiction
care services does not match the potential need of the
estimated over 50 % of drug users among the prison
population.
Since many drug users return to prison various times
with the same or even worse problems of drug use and
infectious diseases, prison administrations have had to
acknowledge the need to tackle addiction, drug use,
related risks and health consequences in a more system-
atic way within prison settings. A recent development in
many EU countries that reflects this is the adoption of
genuine ‘prison drugs strategies’, the provision of direc-
tives on the care and treatment of addicted prisons, or
the development of quality standards for specific ser-
vices (62). Prison drug strategies usually cover a range of
measures to treat prisoners, discourage drug use and
reduce the supply of drugs.
Addiction care
Health care services in prisons are traditionally provided
by the prison’s own health care staff under the authority
of the Ministries of Justice, but prison systems across the
EU and in Norway rely to a large extent on additional
external expertise and resources in the care of drug
users. Striving towards ‘equivalence of care’ between the
community and the prison (Council of Europe, 1993;
WHO, 1993), France, in 1994, and Italy, in 2000, have
moved the responsibility for the care of addicted prison-
ers to their Ministries of Health and thus involved local
and regional health care agencies on a statutory basis.
Concrete cooperation agreements between the judiciary
system and public or non-governmental health services
were also established in Ireland in 1999, Portugal in
1999 and Spain in 2000, to increase the quality and
coverage of care for imprisoned drug users.
External drugs specialists play an important role in the
support to drug users in most, if not all, European prison
systems. However, the extent to which prisons are cov-
ered and the level of service provision vary considerably
between and within countries. Notable exceptions in
terms of coverage are: Scotland, which has drug coun-
sellors in every prison; Spain, where addiction care ser-
vices are available in 71 out of 73 prisons; Sweden,
where a third of the estimated number of inmates with
drug problems were covered by treatment motivation
programmes in the year 2000; and England and Wales,
where since 1999 all prisons have specialised external
teams (CARAT — Counselling, Assessment, Referral
Advice and Throughcare Services) which aim to cover
drug-using prisoners’ needs from intake to aftercare —
although a bottleneck seems to be the lack of referral
possibilities (Spacca, 2002). In Scotland, prisoners 
can now also receive transitional care during the first
12 weeks after release, to facilitate their return to the
community.
The services provided by external agencies are general
drug prevention information and education, treatment
motivation programmes and preparation for release, in-
cluding referral to community-based treatment and to af-
tercare. In Belgium and Greece, non-governmental organ-
isations (NGOs) are so far the primary providers of the lim-
ited services that are available to drug users in prisons. In
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(62) Table 13 OL: Recent prison drug strategies, ministerial directives and service standards in the EU and Norway (online version).
Germany, the history of the work in prisons of external
drugs agencies and of specialised internal drugs services
dates back to the mid-1980s and, in 2000, more than 350
drugs counsellors provided their services in German pris-
ons; however, the coverage of this service varies between
the federal states (Länder). In 2000, the involvement of ex-
ternal professionals continued to be an important trend in
France; and, in Italy, the public drugs services SerT noted
a large increase in client numbers, due to their new re-
sponsibility with regard to prisoners. The Spanish national
strategy on drugs (2000–08) defined the participation of
external specialists in the care of drug users in prisons as a
priority, and multiannual cooperation plans between pris-
ons and NGOs have resulted in more than half of the ad-
diction care services (GAD) in Spanish prisons being
staffed by external NGO experts.
Services provided
Written information materials on drugs and drug-related
infectious diseases seem to be available in most prisons
in the EU and Norway; however, systematic and repeat-
ed opportunities to address prevention issues face-to-
face are rare and often depend on the initiative of exter-
nal agencies or individual prison staff.
Detoxification is in general offered through medical
prison services or in specialised detoxification wards, but
quality guidelines are often lacking. A programme
through which 1 200 to 1 500 prisoners received detox-
ification per year has been described as being provided
in an ‘essentially unstructured and unsupervised fashion,
with no follow-up or medium to long-term planning’
(Department of Justice Equality and Law Reform, 1999).
However, quality standards are starting to be introduced,
for example the prison service order of December 2000
requests that all prisons in England and Wales offer qual-
ified detoxification services.
In some countries, external agencies are also directly in-
volved in providing longer-term treatment of addiction.
Examples are the small intramural programmes for drug
users in Denmark and Norway, which are run by spe-
cialised external drugs agencies (‘import model’), and sub-
stitution treatment in Spanish, French and Italian prisons.
The high coverage in Spain has been achieved through the
massive involvement of external drugs services.
Nine EU countries have structured abstinence-oriented
treatment programmes inside prisons and Norway pro-
vides a treatment motivation programme. The total num-
ber of places is, compared with the estimated number of
prisoners with drug problems, very low. However, in
Spain, 8 984 prisoners participated in the 18 available
drug-free treatment programmes in 2000 and, in England
and Wales, 3 100 entrants were registered in the 50
intensive treatment programmes in 2000/01. In Sweden,
10 % of prison facilities, with a capacity to receive 500
prisoners, are specially reserved for voluntary and com-
pulsory treatment of drug users (Ly´sen, 2001) and, in Fin-
land, 18 % of incoming prisoners participate in alcohol
or drug rehabilitation programmes (Jungner, 2001). In the
Austrian prison Favoriten, specialised exclusively in the
care of addicts, 110 treatment places are available; Den-
mark has 30 places and Ireland has nine. The Norwegian
treatment motivation programme can take 18 prisoners
in charge per year (63).
Except for Greece, Sweden and two Länder in Germany
(Bavaria and Baden-Württemberg), substitution treatment
is now available in prisons in all EU countries and Nor-
way. However, even in countries where a large percent-
age of problem drug users in the community are in sub-
stitution treatment, prisons often follow a detoxification
policy. For example, rates in prisons in Germany and the
Netherlands are thought to be between 1 and 4 %
(Stöver, 2001; WIAD-ORS, 2001) compared to an esti-
mated coverage of 30 to 50 % in the community. Most
prison maintenance policies indicate the treatment only
during short-term sentences, for pregnant drug users, and
for those with long addiction careers or severe mental or
physical health problems. Initiation of substitution treat-
ment in prisons is rare, even though it is legally possible
in most countries. The major exception is Spain, where
substitution rates inside and outside prison corre-
spond (64).
Ten EU countries and Norway run drug-free units or pris-
ons. The purpose of some of them is not only to protect
non-dependent inmates from drugs, but also to provide
treatment for addicts. Prisoners under methadone substi-
tution are usually excluded from drug-free units. The 20
drug-free addiction guidance departments in Dutch pris-
ons can cater for 446 prisoners; however, one third of
the capacity remained unused in 1999. Sweden has 356
places in drug-free units and, in Finland, where current-
ly 10 % of all prison wards are drug free, an expansion
to 50 % is envisaged. Portugal recently opened seven
drug-free units with 195 places, evaluated it as a ‘great
success’ and is planning two more units. An analysis of
research on penitentiary addiction care (Rigter, 1998)
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(63) Table 14 OL: Abstinence-oriented treatment and drug-free units in prisons in selected EU countries and Norway (online version).
(64) Table 15 OL: Substitution treatment in prisons in the EU and Norway (online version).
concluded, however, that there was a shortage of reli-
able and valid results worldwide.
Prevention of infectious diseases
The prevention of the transmission of blood-borne dis-
eases during incarceration has become a priority target
for several prison systems in Europe — also with regard
to the notable increases in pharmaceutical expenditure
due to the treatment of drug-related infections (e.g.
HAART, interferon) that prisons have to cover.
Many countries aim to follow the general principles and
specific recommendations made by the WHO in their
Guidelines on HIV infection and AIDS in prison (WHO,
1993). Several risk-reduction measures are difficult to
implement, because they are politically loaded, meet
resistance from staff and are perceived inadequate in
prison settings. Selected prevention measures of the
WHO guidelines and the extent to which EU countries
and Norway implement them are presented in Table 2.
Even though the coverage of these measures appears still
to be insufficient in many countries, some progress has
been made (65). Needle exchange programmes can be
implemented now in all Spanish prisons (66) and Luxem-
bourg and Portugal are discussing their introduction.
More countries recommend prisoners’ access to diluted
bleach and implementation of this measure has
improved.
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(65) For information on the situation up to 2000, see the web site (http://ar2001.emcdda.eu.int/en/chap2/specific_demand.html#table2).
(66) Except prisons located in Ceuta and Melilla. The autonomous community of Cataluña has its own competence in management
of prisons.
Overview of selected measures to prevent blood-borne diseases in prisons in the EU and NorwayTable 2
Information/education Hepatitis B vaccination Provision of disinfectants Needle/syringe exchange
Belgium ++ but not in all prisons + protocol being developed by MoH + 0
Denmark 0 ++ but coverage very low (2 %) ++ with instructions 0
Germany + n.a. + +
Greece + but provision relies primarily + only one prison + only one prison 0
on external agencies
Spain ++ ++ and encouraged ++ ++
France + ++ ++ 0
Ireland 0 ++ + but ++ recommended by Review 0 Review Group on Prison Health Care 
Group on Prison Health Care, 2001 does not recommend N/S exchange, 
because of risks of attacks
Italy 0 n.a. (mandatory vaccination at age 12, ++ 0
whole population, introduced 
early 1990s)
Luxembourg + ++ 0 0 under discussion
Netherlands + ++ ++ 0
Austria + + (1) ++ with instructions on cleaning 0
Portugal + ++ national vaccination programme ++ in practice: + 0 under discussion
Finland + ++ ++ 0
Sweden 0  depends upon prison 0 decision on general introduction 0 0
of vaccination pending
UK + ++ (Scotland) ++ England/Wales: not easy to access. 0
After pilot study, tablets are being 
made available
Scotland: ++ with instructions
Norway n.a. n.a. 0 health authorities asked prisons to 0
make bleach available
NB: n.a. = information not available
Information/education Disinfectants
0 general written materials 0 not available
+ written materials specifically developed for prison setting + in some prisons
++ prison-specific materials plus safer use training ++ in all prisons (at least in theory)
Hepatitis vaccination Needle/syringe exchange
0 not systematically available 0 not available
+ available in few prisons + programme in few prisons
++ available in all prisons ++ programme in all prisons
Sources: Reitox national reports.
European Network on HIV/AIDS and Hepatitis Prevention in Prisons, Final progress report, WIAD, Bonn, and ORS, Marseilles, December 2001.
(1) Spirig, H. and Ess-Dietz, O. (2001): ‘Preventive measures in Austrian prisons’, in WIAD-ORS, pp. 234–300.
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